The fallen Angel...( Biotech-Rebound Depot ) - 500 Beiträge pro Seite

[nkelchen]

ich werde mein im Dezember 2005 gestartetes Experiment,
hier einmal separat "zum Besten" geben.

Keine Ahnung wie es endet, angefangen hat es sehr gut!

Gruss
nk

[nkelchen]

15.12.2005

ich werde mir mal so 4 bis 5 gefallene Engel aus
der Pharma oder Biotech Branche ins Depot legen.

das sollte ein überschaubares Risiko,
gepaart mit guten Chancen werden (hoffe ich)

nk

[nkelchen]

15.12.2005

also im Depot

NABI Kauf 3,45
SCLN Kauf 2,18

nk

[nkelchen]

19.12.2005

update:

Rebound Depot

im Depot:
NABI Kauf 3,45
SCLN Kauf 2,11

Watchlist:
PCYC (-62%)

nk

[nkelchen]

20.12.2005

update:

Rebound Depot

im Depot:
NABI Kauf 3,45 (Position voll)
SCLN Kauf 2,06 (Position voll)

Watchlist:
PCYC (-62%)

nk

[nkelchen]

21.12.2005

update:

Rebound Depot

im Depot:
NABI Kauf 3,45 (Position voll)
SCLN Kauf 2,06 (Position voll)
PCYC Kauf 3,55 1. Posi

Watchlist:
SRLS

nk

[nkelchen]

27.12.2005

update:

Rebound Depot

im Depot:
NABI Kauf 3,45 (Position voll)
SCLN Kauf 2,06 (Position voll)
PCYC Kauf 3,58 2. Posi

WL:
SRLS/E

nk

[nkelchen]

29.12.2005

im Depot:
NABI Kauf 3,45 (Position voll)
SCLN Kauf 2,06 so.
PCYC Kauf 3,54 so.

nk

[nkelchen]

07.01.2006

Hier mein Rebound Depot.
Das Depot ist natürlich nur eine Position meines ganzen Portfolios.
Schliesslich kann es ja auch ganz anders laufen, als ich es mir gedacht habe....



Leider habe ich zur Zeit keine Kandidaten auf der WL -
aber das wird schon noch kommen

Gruss
nk

[nkelchen]

12.01.2006

Ist vielleicht etwas früh im Jahr -
aber ich brauche noch eine Exit Strategie für
mein Rebound Depot.

Als Beispiel PCYC:
hat vom Tief schon 50% gut gemacht.
Der Sturz war von ca. 9€ auf min. 3,26€

Eine Möglichkeit wäre nach 100% Rebound vom Tief, die Posi
zu halbieren?!

Also bei 6,52 halbieren und die restlichen 50% der Posi
auf Einstieg absichern.

PCYC
52 Week Low $3.26
52 Week High $10.50

Zen -
Du hast bestimmt eine Idee, oder?!

nk
*natürlich bin ich mir im klaren, das es hier auch ganz schnell wieder nach unten gehen kann*

[nkelchen]

12.01.2006

Danke für die Empfehlung!!

Bei der Wahl der Strategie, muss es wie bei der Aufnahme
ins Depot gehen:
Gleiche Kriterien für ALLE Werte.

Es ist also egal, welcher Wert was macht, mein Exit
wird immer schon vorher festgelegt.
Wenn ich mir die Auf`s und Ab`s in den Charts besehe,
kann es ohne Strategie ungemütlich werden.
Und ein SL hilft da ja auch nicht, an solchen Horror Tagen - wie am 19. Dezember bei PCYC!!

nk
*ich werde da noch dran basteln*

[nkelchen]

12.01.2006



wäre vielleicht nicht ratsam, an alte Hoch`s zu glauben.
Der Chart weckt die Hoffnung nicht bei mir.

Die lila Linie könnte evtl eine Marke für`s Exit sein.
nk
*stellt sich dann wieder die Frage:
komplette Position - oder nur die halbe..?*
nk

[nkelchen]

12.01.2006

dazu der 5er SCLN

[nkelchen]

12.01.2006

und NABI

[nkelchen]

12.01.2006

Bin zappelig geworden und habe die Hälfte *250* zu 5,29 verkauft. Die haben immerhin 50% gebracht.

Werde das auch weiterhin so machen.
Es gibt sicher ganz viele tolle Ansätze, wie ich was wann und warum machen könnte -
ich wollte mir mit dem Depot aber keinen Stress machen.

Ergo, nach 50% Gewinn - eine Hälfte raus-basta.
nk

[nkelchen]

12.01.2006

Also Stand Rebound-Depot-De05:

Kapitaleinsatz: 4350€
Gewinn PCYC 360€
Cash:1.100€

Im Depot:
800 SCLN
500 NABI
250 PCYC
Wert:4065€

aktueller Gesamtwert:5.165€
Entwicklung: +17%
Watchlist: leer

bleibt noch die Frage, wann ich die anderen 250PCYC
zurück gebe?!

nk

[nkelchen]

14.01.2006
update



Also Stand Rebound-Depot-De05:

Kapitaleinsatz: 4350€
Gewinn PCYC 360€
Cash:1.100€

Im Depot:
800 SCLN
500 NABI
250 PCYC
Wert:3964€

aktueller Gesamtwert:5.064€
Entwicklung: +16%
Watchlist: leer

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist immer = Einstand.

nk

[nkelchen]

14.01.2006

endlich gefunden:

http://www.nasdaq.com/dynamic/nasdaqbiotech_activity.stm

Company Name Symbol
Abgenix, Inc. ABGX
Accelrys, Inc. ACCL
Adolor Corporation ADLR
Affymetrix, Inc. AFFX
Albany Molecular Research, Inc. AMRI
Alexion Pharmaceuticals, Inc. ALXN
Alkermes, Inc. ALKS
Alnylam Pharmaceuticals, Inc. ALNY
American Pharmaceutical Partners, Inc. APPX
Amgen Inc. AMGN
Amylin Pharmaceuticals, Inc. AMLN
Anadys Pharmaceuticals, Inc. ANDS
Angiotech Pharmaceuticals, Inc. ANPI
Antigenics Inc. AGEN
Arena Pharmaceuticals, Inc. ARNA
ARIAD Pharmaceuticals, Inc. ARIA
ArQule, Inc. ARQL
Array BioPharma Inc. ARRY
AtheroGenics, Inc. AGIX
Axcan Pharma Inc. AXCA
Barrier Therapeutics, Inc. BTRX
BioCryst Pharmaceuticals, Inc. BCRX
Bioenvision, Inc. BIVN
Biogen Idec Inc BIIB
BioMarin Pharmaceutical Inc. BMRN
Biosite, Inc. BSTE
BioVeris Corporation BIOV
Caliper Life Sciences Inc CALP
Cardiome Pharma Corporation CRME
Celgene Corporation CELG
Cell Genesys, Inc. CEGE
Cell Therapeutics, Inc. CTIC
Cephalon, Inc. CEPH
Chiron Corporation CHIR
Connetics Corporation CNCT
CoTherix, Inc. CTRX
Crucell NV CRXL
Cubist Pharmaceuticals, Inc. CBST
CuraGen Corporation CRGN
Curis, Inc. CRIS
CV Therapeutics, Inc. CVTX
Cypress Bioscience, Inc. CYPB
Cytokinetics, Incorporated CYTK
deCODE genetics, Inc. DCGN
Dendreon Corporation DNDN
DepoMed, Inc. DEPO
Digene Corporation DIGE
Discovery Laboratories, Inc. DSCO
Diversa Corporation DVSA
DOV Pharmaceutical, Inc. DOVP
Draxis Health Inc. DRAX
Durect Corporation DRRX
Dyax Corp. DYAX
Encysive Pharmaceuticals Inc ENCY
Endo Pharmaceuticals Holdings Inc. ENDP
Enzon Pharmaceuticals, Inc. ENZN
EPIX Pharmaceuticals, Inc. EPIX
Exelixis, Inc. EXEL
First Horizon Pharmaceutical Corporation FHRX
Flamel Technologies S.A. FLML
Gen-Probe Incorporated GPRO
Gene Logic Inc. GLGC
Genitope Corporation GTOP
Genta Incorporated GNTA
Genzyme General GENZ
Geron Corporation GERN
Gilead Sciences, Inc. GILD
Harvard Bioscience, Inc. HBIO
Hi-Tech Pharmacal Co., Inc. HITK
Hollis-Eden Pharmaceuticals, Inc. HEPH
Human Genome Sciences, Inc. HGSI
ICOS Corporation ICOS
Idenix Pharmaceuticals, Inc. IDIX
Illumina, Inc. ILMN
ImClone Systems Incorporated IMCL
ImmunoGen, Inc. IMGN
Immunomedics, Inc. IMMU
Incyte Corporation INCY
Indevus Pharmaceuticals Inc. IDEV
Inspire Pharmaceuticals, Inc. ISPH
InterMune, Inc. ITMN
Introgen Therapeutics, Inc. INGN
Invitrogen Corporation IVGN
Isis Pharmaceuticals, Inc. ISIS
ISTA Pharmaceuticals, Inc. ISTA
Keryx Biopharmaceuticals, Inc. KERX
Kos Pharmaceuticals, Inc. KOSP
Kosan Biosciences Incorporated KOSN
Lexicon Genetics Incorporated LEXG
LifeCell Corporation LIFC
Luminex Corporation LMNX
MannKind Corporation MNKD
Martek Biosciences Corporation MATK
Medarex, Inc. MEDX
Medicines Company (The) MDCO
MedImmune, Inc. MEDI
MGI PHARMA, Inc. MOGN
Millennium Pharmaceuticals, Inc. MLNM
Momenta Pharmaceuticals, Inc. MNTA
Monogram Biosciences, Inc. MGRM
Myogen, Inc. MYOG
Myriad Genetics, Inc. MYGN
Nabi Biopharmaceuticals NABI
Nastech Pharmaceutical Company, Inc. NSTK
Nektar Therapeutics NKTR
NeoPharm, Inc. NEOL
Neurochem Inc NRMX
Neurocrine Biosciences, Inc. NBIX
NitroMed, Inc. NTMD
Northfield Laboratories Inc. NFLD
Noven Pharmaceuticals, Inc. NOVN
NPS Pharmaceuticals, Inc. NPSP
Nuvelo, Inc. NUVO
ONYX Pharmaceuticals, Inc. ONXX
Orchid Cellmark Inc. ORCH
Oscient Pharmaceuticals Corporation OSCI
OSI Pharmaceuticals Inc. OSIP
Pain Therapeutics PTIE
Panacos Pharmaceuticals, Inc. PANC
PAREXEL International Corporation PRXL
PDL BioPharma, Inc. PDLI
Penwest Pharmaceuticals Co. PPCO
Perrigo Company PRGO
Pharmacyclics, Inc. PCYC
Pharmion Corporation PHRM
Pozen, Inc. POZN
Progenics Pharmaceuticals Inc. PGNX
Qiagen N.V. QGEN
QLT Inc. QLTI
Regeneron Pharmaceuticals, Inc. REGN
Renovis, Inc. RNVS
Rigel Pharmaceuticals, Inc. RIGL
Salix Pharmaceuticals, Ltd. SLXP
Santarus, Inc. SNTS
Savient Pharmaceuticals Inc SVNTE
SciClone Pharmaceuticals, Inc. SCLN
Seattle Genetics, Inc. SGEN
Sepracor Inc. SEPR
Serologicals Corporation SERO
SFBC International, Inc. SFCC
Shire plc SHPGY
Sirna Therapeutics, Inc. RNAI
StemCells, Inc. STEM
SuperGen, Inc. SUPG
Tanox, Inc. TNOX
Taro Pharmaceutical Industries Ltd. TARO
Techne Corporation TECH
Telik, Inc. TELK
Tercica, Inc. TRCA
Teva Pharmaceutical Industries Limited TEVA
Third Wave Technologies, Inc. TWTI
Trimeris, Inc. TRMS
United Therapeutics Corporation UTHR
Vasogen Inc. VSGN
Vertex Pharmaceuticals Incorporated VRTX
ViaCell, Inc. VIAC
ViroPharma Incorporated VPHM
Vivus, Inc. VVUS
XOMA Ltd. XOMA
ZymoGenetics, Inc.
------------------------------------------------------

ins Depot kommen nur an der Nasdaq gelistete Werte.
Aus diesem Grunde habe ich auch SRLS(E)
von der WL entfernt.

nk

[nkelchen]

17.01.2006

Kauf 1.Posi RIGL 100Stück zu 7,92Dollar
=657€

nk

[nkelchen]

19.01.2006

noch mal 50 RIGL zu 7,86
Stand 150 average mit Gebühren 7,913

nu warte ich mal`ne Woche ab, wohin der Chart läuft...
100 Stück sind noch drin.

nk

[nkelchen]

20.01.2006

da heute Kaufkurse sind -
letzte Posi RIGL zu 7,84

nk

[nkelchen]

21.01.2006

update


Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 5050€
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Cash:0€

Im Depot:
800 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:5562€

aktueller Gesamtwert:5922€
Entwicklung: +17,20%
Watchlist: leer

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.

nk

[nkelchen]

27.01.2006

wöchentliches update:



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 5050€
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Cash:0€

Im Depot:
800 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:5484€

aktueller Gesamtwert:5844€
Entwicklung: +15,70%
Watchlist: leer

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.

nk

[nkelchen]

04.02.2006



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 5050€
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Cash:0€

Im Depot:
800 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:5813€
Entwicklung:15,10%

aktueller Gesamtwert:6173€
Entwicklung: +22,22%

Watchlist: RHEO

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.

nk

[nkelchen]

11.02.2006



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 5050€
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Cash:360€ (Depotgewinne, die realisiert wurden)

Im Depot:
800 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:5817€
Entwicklung:15,20%

aktueller Gesamtwert:6174€
Entwicklung: +22,22%

Watchlist: RHEO

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.

nk

[nkelchen]

18.02.2006



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 5050€
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Cash:360€ (Depotgewinne, die realisiert wurden)

Im Depot:
800 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:6110€
Entwicklung:21%

aktueller Gesamtwert:6470€
Entwicklung: +28,12%

Watchlist: RHEO

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.

nk

[nkelchen]

18.02.2006

Folgende Antwort bezieht sich auf Beitrag Nr.: 20.266.528 von brezlbua am 18.02.06 01:24:13
--------------------------------------------------------------------------------


noch 2Sätze zu:
Schade übrigens, dass Ihr in Eurem Rebound-Depot nur Nasdaq Biotech-Werte berücksichtigt. Ich muss sagen, auch in anderen Branchen gibt es mitunter leckere Gelegenheiten. Hatte kürzlich mit XWG (Tech-Zubehör) das Vergnügen: Einstieg bei 5,06, Verkauf ein paar Tage später bei 7,40. Da könnte bald nochmal was gehen.

Mir war zufällig aufgefallen, dass gerade bei diesen Werten
(Biotech-Index) eine hohe draw down Häufigkeit besteht.
Diese draw downs entstehen immer wegen einer negativen Studie, meist in Phase 3.
Ich brauche mich also in all den Fällen nicht grossartig,
fundamental mit dem Unternehmen zu beschäftigen,
denn eine mehr oder weniger grosse pipeline haben die alle.
Einfach einige Wochen abwarten, sehr positiv sind Insiderkäufe und dann rein in den Wert.

Es ist also auch eine gewisse Bequemlichkeit, die mich gerade ein solches Depot(Fonds) hat zusammenstellen lassen.
Zudem mir das studieren etlicher Charts gezeigt hat, das es in vielen Fällen(nicht allen)zu einem Rebound kam.
Zur Zeit ist ELAN so eine Aktie.

Solltest Du Erfahrungen in anderen Branchen schon gemacht haben, nur her damit!!

Gruss
nk

[ipollit]

hier sollte einiges zu finden sein...

www.f-tor.de/board/showthread.php?t=24245&page=1

mfg ipollit

[nkelchen]

[posting]20.271.778 von ipollit am 18.02.06 19:44:58[/posting]

zu FMTI:
ich habe den Chart verlängert.
Die wären natürlich nie in mein Depot gekommen!



nk

[cyberhai]

Hallo nkelchen,

ich finde Deinen Ansatz sehr interessant. Betreibst Du das Depot auch real.

Bei SCLN hatte ich den Absturz mitgemacht, war nicht schön. Bin dann mit einen dicken Verlust raus, natürlich zu früh.

PCYC hatte ich auch im Depot, bin da aber zum Glück ein paar Tage vor dem Absturz raus.

Bei NABI bin ich einige Wochen nach dem Absturz rein und die halte ich aufgrund des Nikotinimpstoffes für sehr aussichtsreich.

Gruß Cyberhai

[nkelchen]

[posting]20.272.046 von cyberhai am 18.02.06 20:19:00[/posting]

Hallo cyberhai -
ja, ist ein reales Depot.

Das Depot überschreitet aber nicht die Grösse,
die bei mir auch eine einzelne Aktie max. besitzen darf!

Was ich dazu noch schreiben sollte,
nur an der Nasdaq ordern, in FFM fast kein Handel.

Gruss
nk
*bin für alle Gedankengänge offen*

[nkelchen]

[posting]20.271.778 von ipollit am 18.02.06 19:44:58[/posting]

Da Du auch CTIC als trauriges Kontra Beispiel erwähnt hattest -

es kommen nur Werte in Frage, wo nach dem Draw down positive Insidertrades stattfinden.

Ergo wird eine RHEO auch nur dann in mein Depot aufgenommen.
Hier gab es vorher sogar kräftige Verkäufe
(was ich gar nicht gerne sehe)

nk

[nkelchen]

[posting]20.272.162 von nkelchen am 18.02.06 20:32:27[/posting]Beispiel SCLN:



http://www.nasdaq.com/asp/Holdings.asp?symbol=SCLN&selected=…

nk

[nkelchen]

[posting]20.272.235 von nkelchen am 18.02.06 20:40:53[/posting]RHEO

so kommen die mir nicht in die Tüte!!!



da müssen erst einmal ein paar hundert k von Insidern
geordert werden!!

nk

[ipollit]

[posting]20.272.162 von nkelchen am 18.02.06 20:32:27[/posting]prinzipiell kein schlechter Ansatz...

der RIGL Insiderkauf war mit 8000 USD eher symbolisch

der Insiderkauf siebt natürlich ziemlich aus...

MDCO... Kauf am 27.10.



PTIE... Kauf am 16.12.ff



SFCC... Kauf am 8.11.ff



TRCA... Kauf am 13.12.ff



KOSN... Kauf am 29.12.



wenn ich nichts übersehen habe, sind das alle

mfg ipollit

[Lanzalover]

interessantes experiment . . .

[cyberhai]

Den Ansatz mit den Insiderkäufen betreibe ich auch. Ich achte allerdings noch verstärkt darauf, ob die Insider dem Unternehmen angehören... Wenn nur Beneficial Owner (10% or more) zukaufen und das Management gar keine, dann steht dieses Unternehmen auf der Kaufliste eher unten...

Gruß Cyberhai

[Cashlover]

guter thread!

[nkelchen]

[posting]20.272.626 von ipollit am 18.02.06 21:23:00[/posting]

Moin -
und Danke für die Kandidaten.
Leider erfüllen sie nicht meine Kriterien
(mindestens 50% Verlust in ein, oder wenigen Tagen)

Ich habe Gestern noch einmal alle Werte gescannt
(so ca. 150)
es gibt zur Zeit für mich nur RHEO als evtl Neuaufnahme.
Es braucht halt noch Insidertrades!

Gruss
nk
*Klasse - ist ja richtig was los hier*

[nkelchen]

hier meine WL Position:



nk

[nkelchen]

[posting]20.274.739 von cyberhai am 19.02.06 10:15:15[/posting]

Danke für den Hinweis!

Ich muss allerdings auch darauf achten, dass nicht
alle möglichen Kandidaten durch ein zu enges Raster fallen.

Gruss
nk

[whyso]

[posting]20.275.177 von nkelchen am 19.02.06 11:01:53[/posting]Gruß dich nkelchen

Alle Achtung, hier hast du ein klasse Titel ausgepackt für ein Threaderöffnung wie ich finde!

Bin etwas müde aber möchte ein paar "evtl." passende namen hier reinbringen:

NVAX:


Marktkapital.225,91 Mio. USD>>>49 Mio Aktien und ein President der alles an Firmen Aktien kauft was nicht festgenagelt http://www.form4oracle.com/company?cik=0001000694&ticker=nva…

GNTA:


Genta leitet bei europäischen Aufsichtsbehörden Zulassungsantrag für Genasense(R) plus Chemotherapie für Patienten mit fortgeschrittenem Melanom ein
http://aktien.onvista.de/news-filter.html?ID_OSI=88568&ID_OS…

Marktkapital.268,88 Mio. EUR >>>Stücke 114 Mio.

Übrigens der Markt für Genasense könnte an der spitze knappe 3 Mrd Dollar Umsatzpotential hergeben

und hier (meine Meinung nach)der Biotech Rebounder schlechtin z.Zt CBMX die Combimatrix mit US Armee aufträge bereits in die tasche für die Micro-ARRAY 90 flu tests...

CBMX:


Marktkapital.62,77 Mio. USD>>Stücke 39 Mio.

CTIC & GENR lalufen auch noch "Brav" neben her....alle dieser Werte handeln an der Nasdaq, und sind völlig ausgebombt gewesen, finden allerdings jetzt langsam aber sicher wieder beine!

Es bleibt jedenfalls weiterhin Spannend mit die fallen angels!!!(tommorows stars???)

Viele Grüße & good trades,
Whyso

P.S. ich halte der GPC Biotech-(12,60€)-für die kommende Börsenstar am deutschen Biotech-Himmel von übermorgen...

[whyso]

CBMX hat man heute leicht "wachgeküsst" stateside...


Much more to come,
Whyso

[nkelchen]

[posting]20.328.520 von whyso am 22.02.06 16:55:25[/posting]

Nichts ist so beständig wie der Wechsel:
Von null auf 2 auf der WL!




GTC Biotherapeutics Expects CHMP to Issue Negative Opinion on ATryn(R)

E-mail | Print | | Disable live quotes Last Update: 7:34 AM ET Feb 23, 2006


FRAMINGHAM, Mass., Feb 23, 2006 (BUSINESS WIRE) -- GTC Biotherapeutics, Inc. (GTCB : gtc biotherapeutics inc com
News , chart, profile, more
Last: 2.25+0.05+2.27%

8:35am 02/23/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
GTCB2.25, +0.05, +2.3%) announced today that it has been told that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) intends to issue a negative opinion on the market authorization application (MAA) for ATryn(R), GTC`s recombinant form of human antithrombin. On the basis of recent conversations, GTC understands that the CHMP, after excluding data from pregnant patients, determined that an insufficient number of surgical patients were enrolled to support approval. In addition, GTC understands that the CHMP has concerns about sufficient immunologic data and the lack of clinical data from ATryn(R) produced with an additional filtration step. GTC intends to take advantage of the appeal process to request a CHMP re-examination of GTC`s submission.
GTC`s European development and commercialization partner, LEO Pharma A/S, has affirmed that they remain committed to their collaboration with GTC and will continue to pursue the primary goal of development of an acquired deficiency indication for Europe. Acquired deficiency indications represent the most significant market opportunity for the product. GTC and LEO entered into a collaborative development and commercialization agreement for ATryn(R) in Europe, Canada, and the Middle East in November 2005. GTC is also continuing a multinational study of ATryn(R) in hereditary antithrombin deficient patients in preparation for submission of a Biologics License Application (BLA) in the U.S. Enrollment is planned to be completed in 2006 and a BLA submitted in the first half of 2007.
"Although we are very disappointed with the late-breaking concerns on the clinical data and the negative opinion, we are pleased by the commitment of LEO Pharma to continue working on further development of this important product in Europe in acquired antithrombin deficiency," stated Geoffrey F. Cox, Ph.D., GTC`s Chairman of the Board and Chief Executive Officer. "In addition we remain committed to completing our submission for BLA approval in the US. The US remains a major long term opportunity for ATryn(R) in a range of hereditary and acquired deficiency indications. It is also important for our transgenic technology platform that the CHMP has not identified to us any significant outstanding issues related to the manufacturing and production control systems for ATryn(R)."
Antithrombin is a protein in human plasma that has anticoagulant and anti-inflammatory properties. Patients that have a hereditary deficiency indication are prone to developing blood clots during high-risk procedures, such as surgery and childbirth. Providing supplemental antithrombin during these procedures may prevent the occurrence of DVT`s and other thromboembolic events. Antithrombin supplementation therapy may also be useful in the treatment of patients who acquire temporary antithrombin deficiency during certain clinical situations such as burns, coronary artery bypass surgery, disseminated intravascular coagulation, sepsis, and bone marrow transplant.
Conference Call Information
GTC will discuss this opinion and the status of ATryn(R) in a web cast conference call at 9:00 a.m. (Eastern) today. The web cast may be heard through GTC`s web site at www.gtc-bio.com. The dial-in number from inside the United States is 1-800-901-5231. The dial-in number from outside the United States is 1-617-786-2961. The participant passcode is 41916712.
About GTC Biotherapeutics, Inc.
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. In addition to the ATryn(R) program, GTC is developing recombinant human alpha-1 antitrypsin, recombinant human albumin, a CD137 antibody as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC`s technology is used to develop transgenic production of its partners` proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding its expectations for the final CHMP opinion, the development of an acquired deficiency indication with LEO, the ongoing phase III study and preparation of a BLA, and GTC`s request for a CHMP re-examination of the submission. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC`s most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the uncertainties associated with regulatory approval and the actions of partners. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.
SOURCE: GTC Biotherapeutics, Inc.
GTC Biotherapeutics, Inc. Thomas E. Newberry, 508-370-5374 or Feinstein Kean Healthcare for GTC Biotherapeutics, Inc. Francesca DeVellis, 617-577-8110 Copyright Business Wire 2006 ********************************************************************** As of Sunday, 02-19-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 11-03-2005 for GTCB @ $1.71. (C) 2006 Comtex News Network, Inc. All rights reserved

[puhvogel]

[posting]20.343.609 von nkelchen am 23.02.06 14:53:03[/posting]Sicher nicht so furchtbare Gewinne in aussicht, ich denke ein guter Turnaround-Kandidat mit einem KGV von etwa 15.
http://www.axcan.com/pdf/Q1_2006.pdf
Der letzte Quartalsbericht

Axcan ist mit seinen Nischenprodukten ziemlich breit aufgestellt und jetzt gefallen , weil deren Hoffnungsträger in Phase 3 ziemlich überraschend durchgefallen ist.
Cash (125 Millionen USD) ist gleich den Convertibles, die 2008 anfallen.
Sicher kein 10 Bagger

[nkelchen]

[posting]20.350.216 von puhvogel am 23.02.06 20:04:30[/posting]

ich möchte die Qualität der Aktie nicht in Frage stellen.
Das Gap ist aber zu klein für meine Aufnahme Kriterien.
Waren ja nur 25% Wertverlust.

*50% an einem, oder einigen wenigen Tagen!*

Gruss
nk

[puhvogel]

@nkelchen: Sorry, habe ich überlesen! Nix für ungut!

[nkelchen]

[posting]20.351.890 von puhvogel am 23.02.06 21:32:23[/posting]

@ puhvogel -
nix sorry, jeder Beitrag zum Thema ist erwünscht.
(also auch #45)

wöchentliches update:

die Woche war doch sehr durchwachsen, vor allem NABI
(es gab Q-uns J-Zahlen)
brach ein.
Für GTCB hat es dann doch nicht ganz für die Watchlist gelangt.



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 5050€
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Cash:360€ (Depotgewinne, die realisiert wurden)

Im Depot:
800 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:5821€
Entwicklung:15,2%

aktueller Gesamtwert:6181€
Entwicklung: +22,4%

Watchlist: RHEO

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.

nk

[nort.]

Lesezeichen

[nkelchen]

schon ein paar Tage alt:
---------------------------

Press Release Source: Rigel Pharmaceuticals, Inc.


Rigel Announces Completion of R788 Plus Methotrexate Drug Interaction Study in Patients with Rheumatoid Arthritis
Wednesday February 22, 7:30 am ET
Company to Initiate Further Clinical Studies of R788 in Rheumatoid Arthritis and in Immune Thrombocytopenic Purpura Later This Year


SOUTH SAN FRANCISCO, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced preliminary data from a Phase I double-blind, placebo controlled trial to investigate the safety and pharmacokinetics of R788, an oral syk kinase inhibitor, in combination with methotrexate in rheumatoid arthritis (RA) patients. The data demonstrated that R788 was well tolerated when given in combination with methotrexate and had no significant adverse pharmacokinetic interactions. The company also announced plans to initiate separate clinical efficacy studies with R788, in RA and in Immune Thrombocytopenic Purpura (ITP), in the second half of 2006.
ADVERTISEMENT


" New, effective therapeutic options in RA are greatly needed since current treatments have potentially significant limitations," stated Elliott B. Grossbard, M.D., senior vice president of medical development at Rigel. " We are pursuing R788 in autoimmune diseases such as RA and ITP because it has been shown to be a potent and selective inhibitor of syk kinase, which may play a key role in autoimmune diseases."

The Phase I study enrolled patients verified to suffer from RA and who were receiving methotrexate treatment. There were no unanticipated adverse events and pharmacokinetic analysis suggests that there is no adverse interaction with the two agents.

About R788

R788 is a novel, oral syk kinase inhibitor that blocks the activation of mast cells, macrophages and B cells that promote swelling and an inflammatory response. It is being developed initially to treat RA. Phase I trial results have demonstrated that R788 is well-tolerated and showed good pharmaceutical properties. Earlier Phase I studies generated valuable pharmacokinetic/pharmacodynamic data establishing a strong correlation between drug plasma levels and the inhibition of the drug target. In preclinical studies, Rigel`s compound greatly diminished the swelling and tissue destruction associated with RA. In addition, in a murine model of ITP, the drug increased platelet counts significantly.

Rheumatoid Arthritis: Current Treatments and Market Opportunity

Approximately 2.1 million people in the U.S. suffer from RA and the worldwide market for innovative RA drugs is projected to reach $10 billion by 2008. RA is a chronic inflammatory disease that affects multiple tissues, but typically produces its most pronounced symptoms in the joints. It is often progressive and debilitating, preventing people from living a symptom-free life. Ultimately the chronic inflammation of joints leads to the destruction of the soft tissue and erosion of the articular surfaces of the bone.

The current treatment options for RA have potentially significant side effects and other shortfalls, including gastrointestinal complications and kidney damage. Some RA patients currently receive multiple drugs depending on the extent and aggressiveness of the disease. Most RA patients require some form of DMARD -- including methotrexate, an anti-cancer agent, or TNF-blocking agents such as Enbrel®. The TNF-blocking agents only inhibit the inflammatory mediator TNF, and are all delivered via injection. Rigel believes that there is a significant opportunity for an oral DMARD that can be used earlier in the course of the disease, preventing its progression prior to major bone and cartilage destruction; this is the product goal for R788 in RA.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel`s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, asthma and allergy, as well as in cancer.

This press release contains " forward-looking" statements, including statements related to Rigel`s plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy and safety of product candidates, and the opportunity of a DMARD. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as " plans," " intends," " expects," " believes," " goal," " suggests," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel`s results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel`s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. Rigel does not undertake any obligation to update forward-looking statements.


CONTACT:
Raul Rodriguez
[phone]
[e-mail]

MEDIA CONTACT:
Carolyn Bumgardner Wang
WeissComm Partners, Inc.
[phone]
[e-mail]





das waren gestern ordentliche Umsätze!
Mal abwarten, ob die 9,80 weiter zugemauert wird...
nk

[nkelchen]

Empfehlung für NABI

http://finance.yahoo.com/q/sa?s=nabi

[nkelchen]

[posting]20.430.969 von nkelchen am 28.02.06 19:56:05[/posting]

SciClone Pharma quarterly loss narrows, sales rise

(6:42 AM ET) LONDON (MarketWatch) -- SciClone Pharmaceuticals, Inc.(SCLN)posted a fourth-quarter net loss that narrowed to $1.6 million, or 4 cents a share, from $2.4 million, or 5 cents a share, in the year-earlier period. Revenue rose to $7.4 million from $6.1 million on a 22% jump in sales of Zadaxin, SciClone`s lead product. The company predicted Zadaxin sales will rise to about $32 million in 2006, driven by continued growth in China. Net loss in 2006 is estimated at about 13 cents a share.

[nkelchen]

[posting]20.442.617 von nkelchen am 01.03.06 14:24:24[/posting]

heute wird einfach nur gefeiert...


nk
*wer weiss, was Morgen ist..*

[nkelchen]

Rigel Pharmaceuticals, Inc. (PRNewsFoto)

SOUTH SAN FRANCISCO, CA USA 02/17/2005



SOUTH SAN FRANCISCO, Calif., March 1 /PRNewswire-FirstCall/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the
company`s chairman and chief executive officer, is scheduled to present at the
Ninth Annual Lehman Brothers Global Healthcare Conference on Wednesday, March
8th at 3:15 p.m. EST. The conference will be held at the Loews Miami Beach
Hotel in South Beach.
To access the live audio webcast or the subsequent archived recording, log
on to http://www.rigel.com/rigel/events." target="_blank" rel="nofollow ugc noopener">http://www.rigel.com/rigel/events. Please connect to Rigel`s website several
minutes prior to the start of the live webcast to ensure adequate time for any
software download that may be necessary.

About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and
develops novel, small-molecule drugs for the treatment of inflammatory
diseases, cancer and viral diseases. Our goal is to move one new product
candidate for a significant indication into the clinic each year. We have
achieved this goal since 2002. Our pioneering research focuses on
intracellular signaling pathways and related targets that are critical to
disease mechanisms. Rigel`s productivity has resulted in strategic
collaborations with large pharmaceutical partners to develop and market our
product candidates. We have product development programs in
inflammatory/autoimmune diseases such as rheumatoid arthritis,
thrombocytopenia, asthma and allergy, as well as in cancer.

This press release contains "forward-looking" statements, including
statements related to Rigel`s plans to pursue clinical development of product
candidates and the timing thereof and the potential efficacy and safety of
product candidates. Any statements contained in this press release that are
not statements of historical fact may be deemed to be forward-looking
statements. Words such as "plans," "intends," "expects," "believes," and
similar expressions are intended to identify these forward-looking statements.
There are a number of important factors that could cause Rigel`s results to
differ materially from those indicated by these forward-looking statements,
including risks associated with the timing and success of pre-clinical studies
and clinical trials, as well as other risks detailed from time to time in
Rigel`s SEC reports, including its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2005. Rigel does not undertake any obligation to
update forward-looking statements.

Contact: Jim Welch
Phone: [phone]
Email: [e-mail]



SOURCE Rigel Pharmaceuticals, Inc.
Web Site: http://www.rigel.com
Photo Notes: NewsCom:
http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO AP Archive:
http://photoarchive.ap.org PRN Photo Desk
[e-mail]

--------------------------------------------------------------------------------

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2006 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.

[nkelchen]

was macht der mögliche Depot Kandidat:
------------------------------


Breaking News
Email article to a colleague Printer friendly version
OccuLogix to Release Fourth Quarter & Full Year 2005 Financial Results and Provide a MIRA-1 Analysis Update on March 9-Conference Call to Follow
3/1/2006 1:00:00 PM EST

OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) expects to announce fourth quarter and full-year 2005 financial results before market open on Thursday, March 9, 2006. In a separate press release on March 9, the Company also plans to provide an update on the analysis of MIRA-1, its recently completed pivotal (phase III) clinical trial using its RHEO(TM) System to treat the dry form of age-related macular degeneration.

OccuLogix is pleased to invite all interested parties to participate in a conference call during which both the financial and clinical results will be discussed. The call will be held on March 9, at 8:30 a.m. Eastern Time at 800-640-7112 (within the United States and Canada), or 416-620-2406 (international callers).

The call will be broadcast live and archived on the company`s website at www.occulogix.com under the "webcasts" link in the Investor Relations section. In addition, the live webcast will be available at various other popular portals and financial web sites.

For those wishing to listen to a recording of the call via telephone, a replay will be made available as soon as possible after the conclusion of the live call and will remain posted for a period of fourteen days. To listen to the recording, simply telephone [phone] and enter reservation # 21284926 when prompted.

About OccuLogix

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market. OccuLogix`s common shares trade on the NASDAQ National Market under the symbol `RHEO` and on the Toronto Stock Exchange under the symbol `RHE`. Visit us on the internet at www.occulogix.com (corporate) and www.rheo.com (healthcare professionals, patients and caregivers).

Forward Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities, including our Registration Statement on Form S-1. We do not undertake to update any forward-looking statements.

OccuLogix, Inc. (NASDAQ:RHEO) (TSX:RHE)

CONTACT:
OccuLogix, Inc. Stephen Kilmer VP, Corporate Affairs [phone] ext. 3904 [e-mail]

Email article to a colleague Printer friendly version
<< back

[nkelchen]

wöchentliches Update:


Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 5050€
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Cash:360€ (Depotgewinne, die realisiert wurden)

Im Depot:
800 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:6203€
Entwicklung:22,8%

aktueller Gesamtwert:6563€
Entwicklung: +30%

Watchlist: RHEO

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.

nk

[whyso]

[posting]20.504.816 von nkelchen am 04.03.06 13:21:26[/posting]@Nkelchen,

achte auf CBMX ab nächste Woche

Dort bahnt sich die "Mutter alle Rebounds" so langsam an, wäre schade wenn du den Boot verpassen solltest..

Schönes Wochenende!
Whyso

P.S. Ich halte auch die Greenshift GSHF.OB (Bio Petroleum) für ein sehr aussichtsreiche Pennystock Aktie zurzeit...(obwohl es kein Biotech Wert ist, & an noch an der OTC handelt)

[nkelchen]

[posting]20.506.064 von whyso am 04.03.06 14:27:21[/posting]

Hallo Du Whisky Experte -
werde mir den Wert einmal anschauen!

Gruss
nk

[whyso]

[posting]20.510.079 von nkelchen am 04.03.06 16:47:22[/posting]Na Nkelchen, was habe ich dir gesagt?



und wir stehen wirklich hier am Anfang-hier findest du ein paar Gründe "wieso": Thread: Acacia Research-(CBMX)-die CombiIMatrix- Vogelgrippe Play & rebounder 2006 ???

Beste Grüße,
Whyso

[nkelchen]

[posting]20.534.339 von whyso am 06.03.06 14:08:22[/posting]


Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 5050€
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Cash:360€ (Depotgewinne, die realisiert wurden)

Im Depot:
800 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:6300€
Entwicklung:24,8%

aktueller Gesamtwert:6660€
Entwicklung: +31,9%

Watchlist: RHEO

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Insiderkäufe nach dem draw down, sind für eine
Depotaufnahme unablässig.

nk

[nkelchen]

[posting]20.626.242 von nkelchen am 11.03.06 08:46:49[/posting]

bis auf PCYC, sehen die Charts richtig gut aus!
Beispiel NABI



nk

[nkelchen]

[posting]20.634.961 von nkelchen am 11.03.06 19:23:08[/posting]

Hello and welcome!!!
Futter für meine WL:
-----------------------


OrthoLogic dives on poor drug data

E-mail | Print | | Disable live quotes By Val Brickates Kennedy, MarketWatch
Last Update: 11:37 ET Mar 15, 2006


BOSTON (MarketWatch) -- Shares of OrthoLogic Corp. plunged Wednesday as investors reacted to initial data from a late-stage clinical trial showing that drug candidate Chrysalin was largely ineffective in treating unstable wrist fractures.
OrthoLogic (OLGC : Orthologic Corp
News , chart, profile, more
Last: 2.64-2.54-49.08%

12:54pm 03/15/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
OLGC2.64, -2.54, -49.1%) lost 48% to trade at $2.70 by late morning.
In a release, Tempe, Ariz.-based OrthoLogic said that Chrysalin, a synthetic peptide product, did not prove to be statistically more beneficial than a placebo in speeding up the healing of unstable, displaced wrist fractures during a Phase III clinical trial, in which 503 patients had been enrolled.
"We will be conducting a full examination of these results in order to guide our program," said Chief Executive James Pusey in a statement.
OrthoLogic expects to release the results of its analysis during the third quarter, the company said.
Val Brickates Kennedy is a reporter for MarketWatch in Boston.


nk

[nkelchen]

[posting]20.706.375 von nkelchen am 15.03.06 19:11:27[/posting]

[nkelchen]

soll ich
oder


50% Schwelle überschritten:

halbe Position SCLN zu 3,07Dollar liquidiert!
Es verbleiben also noch 400 Aktien im Depot.
Gewinn 327€

nk

[nort.]

nkelchen,

schau Dir mal bei Gelegenheit CBMX an. Ebenfalls ein fallen angel

NABI sieht absolut perfekt aus

nort

[nkelchen]

[posting]20.741.267 von nort. am 16.03.06 19:50:13[/posting]

hallo nort -
werde ich mir anschauen!!

update:



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 4375€ (Wechselkurs 1,20)
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Gewinn SCLN 328€ (50%Gewinn-16.03.2006)
Cash:668€ (Depotgewinne, die realisiert wurden)

Im Depot:
400 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:5595€
Entwicklung:%27,8

aktueller Gesamtwert:6263€
Entwicklung: +43,1%

Watchlist: RHEO/OLGC

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Insiderkäufe nach dem draw down, sind für eine
Depotaufnahme unablässig.

nk

[nkelchen]

damit alles seine Ordnung hat:


nk

[nkelchen]

[posting]20.741.267 von nort. am 16.03.06 19:50:13[/posting]

Hallo nort,
CBMX erfüllt leider nicht meine Depot Kriterien.
Es fehlt halt ein Gap von ca. 50% oder mehr.
Trotzdem Danke für den Hinweis.
Gruss
nk

[whyso]

Die offene Gap kriteria wird CBMX "baldigst" schliessen, hier sind alle Zutaten für ein gewaltigen Anstieg längst im Topf, wir fangen alleridings erst jetzt an zu kochen

[nkelchen]

update:



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Stand Rebound-Depot-De05:

Kapitaleinsatz: 4375€ (Wechselkurs 1,20)
Gewinn PCYC 360€ (50%Gewinn-12.01.2006)
Gewinn SCLN 328€ (50%Gewinn-16.03.2006)
Cash:668€ (Depotgewinne, die realisiert wurden)

Im Depot:
400 SCLN
500 NABI
250 PCYC
225 RIGL
Wert:5649€
Entwicklung:%29,1

aktueller Gesamtwert:6317€
Entwicklung: +44,4%

Watchlist: RHEO/OLGC

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
`zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Insiderkäufe nach dem draw down, sind für eine
Depotaufnahme unablässig.

nk

[nkelchen]

SciClone gets U.S. FDA orphan drug designation
Mon Mar 20, 2006 6:47 AM ET
Printer Friendly | Email Article | Reprints | RSS

NEW YORK, March 20 (Reuters) - SciClone Pharmaceuticals Inc. (SCLN.O: Quote, Profile, Research) on Monday said thymalfasin, the chemical composition of Zadaxin, received an orphan drug designation for malignant melanoma from the U.S. Food and Drug Administration.

The company said it expected to report additional tumor response data and preliminary survival information from this trial later in 2006.



© Reuters 2006. All Rights Reserved.

[nkelchen]

Press Release Source: Rigel Pharmaceuticals, Inc.


Rigel Granted Key Patents in Immunology, Virology and Oncology
Tuesday March 21, 7:30 am ET
29 Patents Issued in Past 24 Months


SOUTH SAN FRANCISCO, Calif., March 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that it has been awarded 29 patents since February 2004. Specifically, Rigel was granted six patents in immunology, five patents related to its ubiquitin ligase technology, four patents related to hepatitis-C (HCV), six patents in oncology, four patents towards its library screening technology, and four patents in Fluorescence- Activated Cell Sorter (FACS) technology. Rigel is ranked as one of the top 15 biotech companies in the February 10, 2006 San Francisco Business Times` annual listing of the largest biotech patent recipients in the San Francisco Bay Area, based on the number of patents assigned in 2005.
ADVERTISEMENT


"Rigel remains on the forefront of ligase research, and has significant research and development expertise in immunology, virology and oncology where we have been identifying and developing novel, small-molecule drugs," said Donald G. Payan, M.D., executive vice president and chief scientific officer of Rigel. "The large number of patents we have received over the past year exemplifies our productivity in these key disease areas."

Of particular interest are several broadly enabling patent estates that have been issued to Rigel and cover key areas of drug discovery. These include:

Ligase

Rigel`s ligase patent estate includes five issued patents and one allowed patent in the United States. The patents cover methods for identifying and/or measuring ubiquitin ligase activity in any disease state and screening for agents that modulate their activity using any of the major enzymes in the ligase pathway as well as particular enzymes. This means the patented subject matter covers screens using any ubiquitin activating enzyme (E1), any ubiquitin conjugating enzyme (E2) or any ligase (E3) as the drug target. Rigel has had two major collaborations based on these proprietary screens.

IRES

Rigel has several issued patents covering screening for antiviral agents where IRES (internal ribozyme entry site) is the drug target. The IRES controls viral translation and protein synthesis, making it an important drug target.

FACS

Rigel`s FACS patent estate covers patents issued in both the U.S. and Europe. FACS assays are used to investigate gene expression and characterize a given drug`s impact on diseased or healthy cells, and are capable of measuring multiple parameters at one time. Rigel`s patents cover FACS assays that measure a minimum of three parameters, which affect different disease states such as cancer and allergy-related disorders, and the cells` response to drugs.

Rigel is pursuing opportunities to license these patent(s) to potential partners that are working in these areas. For more information please contact Rigel`s Business Development and Licensing Department at: [e-mail] or 650-624-1142.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel`s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the potential value of Rigel`s patent portfolio or its development programs, Rigel`s plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy and safety of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects," "believes," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel`s results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel`s SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005. Rigel does not undertake any obligation to update forward-looking statements.


Contact: Raul Rodriguez
Phone: [phone]
Email: [e-mail]

Media Contact: Carolyn Bumgardner Wang, WeissComm Partners, Inc.
Phone: [phone]
Email: [e-mail]




--------------------------------------------------------------------------------
Source: Rigel Pharmaceuticals, Inc.

[nkelchen]

Man träumt ja immer etwas, wenn man an der Börse etwas ausprobiert, aber dass die Sache so geil läuft...

50% Gewinnregel kommt zum 3.Mal zum Zuge:


nk

*langsam brauche ich was Neues für`s Depot*

[puhvogel]

Es ist die richtige Zeit für diese Strategie...

[nkelchen]

mal sehen, ob ich mangels Kandidaten ein Problem bekomme.
Meine Kriterien will ich nicht aufweichen.

Gruss
nk

[nkelchen]

Antwort auf Beitrag Nr.: 20.909.256 von nkelchen am 22.03.06 15:58:06

heute noch ein WL Kandidat?



Antigenics Reports Phase 3 Results for Oncophage in Kidney Cancer; Study Did Not Meet Endpoints; Number of Events Insufficient for Analysis

E-mail | Print | | Disable live quotes Last Update: 8:30 AM ET Mar 24, 2006


NEW YORK, Mar 24, 2006 (BUSINESS WIRE) -- Antigenics Inc. (AGEN : antigenics inc del com
News , chart, profile, more
Last: 2.91-2.20-43.05%

10:00am 03/24/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
AGEN2.91, -2.20, -43.1%) :
-- Independent Panel Review Found Number of Events That Occurred Was Significantly Lower Than That Reported by Investigators
-- Company to Focus on Further Data Analysis and Early-Stage Development Programs
-- Conference Call Scheduled for 9 a.m.
Antigenics Inc. (AGEN : antigenics inc del com
News , chart, profile, more
Last: 2.91-2.20-43.05%

10:00am 03/24/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
AGEN2.91, -2.20, -43.1%) today announced top-line results from its Phase 3 study of Oncophage(R) (vitespen) in kidney cancer patients who are at high risk of recurrence after surgery. The analysis was triggered based on the number of events (defined as recurrence of disease or death of a patient prior to recurrence) reported by study investigators. However, an independent review by the trial's Clinical Events Committee (CEC) revealed that a substantially smaller number of events had actually occurred. The analysis showed a trend in favor of Oncophage for recurrence-free survival (the study's primary endpoint), and a trend against Oncophage for overall survival (secondary endpoint); both findings were not statistically significant.
The results of the CEC review revealed that the required number of events to conduct analysis of the recurrence-free survival endpoint was not met. The analysis of the overall survival endpoint is considered an interim assessment. At this time it is unclear as to why opposing trends were observed between recurrence-free survival and overall survival. There is no readily apparent adverse safety signal associated with the vaccine that the company believes could be contributing to this finding. Antigenics is continuing to conduct a thorough review of the safety and efficacy data, and plans to meet with the US Food and Drug Administration at the end of April to discuss the findings from this trial.
The company expects to subsequently present these data at scientific meetings and will work with study investigators to publish the findings in a peer-reviewed medical journal.
"We believe that further work is necessary to properly interpret these results," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "Upon completion of full analysis of the data, we will further refine our Oncophage strategy, which includes testing Oncophage in combination with other agents, and development of a higher-activity Oncophage. We will move expeditiously and in a fiscally responsible manner to complete this process in the coming weeks."
The Phase 3, randomized, international, multicenter, open-label trial (C-100-12) involved 728 eligible patients whose renal cell carcinoma was at high risk of recurrence after nephrectomy (surgical removal of the diseased kidney). Patients were randomized in a 1:1 ratio into two arms: nephrectomy plus Oncophage vaccination (treatment arm) or nephrectomy alone (observation arm). The arms were well balanced for all known prognostic factors. Although the study protocol required that eligible patients be free of disease at baseline, an independent review by the trial's Clinical Events Committee subsequently found that of the 728 patients enrolled in the trial, 124 had disease at baseline. Furthermore, of the 218 events reported by investigators, 92 of these occurred in patients who had metastatic or residual disease at baseline. These patients should have been deemed ineligible for the trial but were included in the intent-to-treat (ITT) analysis, per statistical convention. The CEC consisted of two primary radiologists who reviewed all available patient images, and an adjudicating radiologist and oncologist.
Next Steps
In view of these results, the company has decided to suspend Part 2 of the kidney cancer trial until the data from Part 1 are fully analyzed. Antigenics expects additional analysis of the data will be completed within the next four to six weeks, with full analysis to be presented at a scientific meeting. The company will continue to follow the large number of patients in the trial who have yet to undergo an event (disease recurrence or death). Patients who are currently receiving Oncophage in the trial will continue to receive vaccine, as will patients in other ongoing Oncophage studies.
Antigenics will also implement a restructuring plan, with the expectation of further reducing its burn rate immediately. This restructuring will involve temporarily discontinuing all late-stage clinical programs and concentrating on Phase 1 and preclinical programs, including Aroplatin(TM), AG-707, higher-activity Oncophage and AU-801. In addition, Antigenics will continue to support and develop its QS-21 business partnerships, with the goal of generating royalties as early as 2009.
Conference Call Information
Antigenics executives will host a conference call at 9:00 a.m. ET today. To access the live call, dial 888.271.9082 (domestic) or 706.679.7741 (international); the access code is 7125894. The call will also be webcast and will be accessible from the company's website at www.antigenics.com/webcast/. A replay will be available approximately two hours after the call through midnight ET on April 7, 2006. The replay number is 800.642.1687 (domestic) or 706.645.9291 (international), and the access code is 7125894. The replay will also be available on the company's website approximately two hours after the live call.
About Antigenics
Antigenics is a biotechnology company working to develop treatments for cancers, infectious diseases and autoimmune disorders.
his press release contains forward-looking statements, including statements regarding the company's planned analysis of the Oncophage Part 1 trial data; the potential publication of such data and the future development of Oncophage; the company's plans for restructuring and reduction of its burn rate; its future preclinical and Phase 1 clinical programs involving Aroplatin, AG-707, higher-activity Oncophage and AU-801; and its corporate partnering activities, including future revenue from such collaborations involving Aroplatin and QS-21. These risks and uncertainties include, among others, the risk of unfavorable data resulting from further analysis of the Oncophage Part 1 trial data; retention of key employees; clinical trial enrollment; decisions by corporate partners; decisions by regulatory agencies; timing and results of preclinical studies; and the factors described under Factors That May Impact Future Results in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Antigenics' Form 10-K as filed with the Securities and Exchange Commission on March 15, 2006. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.
SOURCE: Antigenics Inc.
for Antigenics Inc. Corporate Communications: Sunny Uberoi, 212-994-8206 [e-mail] or Investor Relations Shalini Sharp, 800-962-2436 [e-mail] Copyright Business Wire 2006 ********************************************************************** As of Monday, 03-20-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-20-2006 for AGEN @ $5.76. (C) 2006 Comtex News Network, Inc. All rights reserved.

[nkelchen]

Antwort auf Beitrag Nr.: 20.939.753 von nkelchen am 24.03.06 16:16:33

noch ein möglicher WL Kandidat:

Shares of Encysive Pharmaceuticals Inc. (ENCY : encysive pharmaceuticals inc com
News , chart, profile, more
Last: 9.08-0.37-3.92%

8:09am 03/27/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:

Ameritrade. Get a Treo™ smartphone.ENCY9.08, -0.37, -3.9%) plunged in pre-market action after the drugmaker said it received a notice from the Food and Drug Administration related to its pulmonary arterial hypertension drug Thelin containing "concerns and observations that must be satisfied prior to achieving approval, including a request for additional clinical trial work." In a statement released late Friday, the biotechnology company said the concerns were contained in an "approvable letter" sent by the FDA.

[nkelchen]

Antwort auf Beitrag Nr.: 20.959.953 von nkelchen am 27.03.06 15:25:29

keine Atempause, Geschichte wird gemacht, es geht voran...

neues aD high 3,60



SciClone Reveals Positive Data From Phase 2 Liver Cancer Trial - Quick Facts

Monday, March 27, 2006; Posted: 06:52 AM

Find out where SCLN is going
Use our most popular trading tool to find
out how SCLN will move in the next
5 days.




Stocks rated 9 and 10 have outperformed the average stock by approximately 14 to 1 since 1995 and ideally are the stocks to focus on each day. Stocks rated 1 and 2 on average have lost money and you want to know these stocks in order to avoid them.

Click here for more details



(RTTNews) - SciClone Pharmaceuticals, Inc. (SCLN | charts | news | Powerrating) reported positive data from its phase 2 hepatocellular carcinoma, or primary liver cancer, trial.

SciClone noted that these data in late 2005, which showed a median survival of 994 days for the 12 patients who received ZADAXIN plus trans-arterial chemoembolization (TACE | charts | news | Powerrating), compared with a median survival of only 399 days for the 13 patients who only received TACE. A positive trend in median survival was observed for patients who received ZADAXIN plus TACE, compared with patients who only received TACE, the company said.

Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved

[nkelchen]

Antwort auf Beitrag Nr.: 20.964.071 von nkelchen am 27.03.06 19:07:40

update mit Verspätung:
(da WO ja nix auf die Reihe bringt...)

Werde mein Depot nun in Dollar führen.



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:


Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Cash:1317$ (Depotgewinne, die realisiert wurden)

Im Depot:
400 SCLN
250 NABI
250 PCYC
225 RIGL
Wert:5304$
Entwicklung:45,8%

aktueller Gesamtwert:6621€

Watchlist: RHEO/OLGC/AGEN/ENCY

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
'zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Insiderkäufe nach dem draw down, sind für eine
Depotaufnahme unablässig.

nk

[nkelchen]

Antwort auf Beitrag Nr.: 20.965.372 von nkelchen am 27.03.06 20:24:53

sorry, muss Dollar sein!

aktueller Gesamtwert:6621$

[nkelchen]

Antwort auf Beitrag Nr.: 20.971.149 von nkelchen am 28.03.06 11:22:06

update:
RIGL fehlen noch 5%...




Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:


Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Cash:1317$ (Depotgewinne, die realisiert wurden)

Im Depot:
400 SCLN
250 NABI
250 PCYC
225 RIGL
Kapitaleinsatz:3637$
Wert:5424$
Entwicklung:49,10%

aktueller Gesamtwert:6741$

Watchlist: RHEO/OLGC/AGEN/ENCY

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
\'zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Insiderkäufe nach dem draw down, sind für eine
Depotaufnahme unablässig.

nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.039.745 von nkelchen am 01.04.06 09:15:47

kleiner Nachtrag:

die WL ist ja nun gut besetzt,
leider fehlen aber immer noch die nötigen Insiderkäufe!
Fazit:
Alle WL Werte auf walking b(u)y...

nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.039.763 von nkelchen am 01.04.06 09:20:29

--------------------------------------------------------------------------------



SciClone Announces Settlement of Schering Plough KK (SPKK) Dispute
SAN MATEO, CA -- (MARKET WIRE) -- 04/03/2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has reached a settlement in its dispute with SPKK concerning clinical trials conducted in Japan with ZADAXIN®, SciClone's lead compound. Under this resolution, SciClone will receive $8,000,000 from SPKK.

"We are pleased to reach a mutually acceptable resolution to our past differences, and we believe that the settlement is fair," stated Dr. Ira Lawrence, President and Chief Executive Officer of SciClone Pharmaceuticals, Inc. "Moving forward at SciClone, we plan to consider the option of pursuing further clinical development in Japan with ZADAXIN, although our immediate focus for ZADAXIN remains on the pursuit of regulatory approvals in the United States and Europe."

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products to market in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.

The information in this press release contains forward-looking statements including our expectations and beliefs regarding progress and results of our clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, goals, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including changes in demand for ZADAXIN, the progress or failure of clinical trials, our actual experience in executing on our objectives, the performance of our partners, maintenance of the sufficiency and eligibility of the enrolled patient population, unanticipated delays or additional expenses incurred during our clinical trials, our future cash requirements, delays in analyzing and synthesizing data obtained from clinical trials, future actions of our strategic partners, unexpected delays in preparation for enrollment, future actions by the U.S. Food and Drug Administration or equivalent regulatory authorities in Europe and the fact that experimental data and clinical results derived from studies with a limited group of patients may not be predictive of the results of larger studies, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.






--------------------------------------------------------------------------------


Corporate information contact:
Becky Horner
Investor Relations
SciClone Pharmaceuticals, Inc.
650-358-3437


SOURCE: SciClone Pharmaceuticals, Inc.

[nkelchen]

Antwort auf Beitrag Nr.: 21.051.672 von nkelchen am 03.04.06 13:08:49

Biotech/Pharma Roundup
Drug Stocks Fall As Big Pharma Shops For Growth
Peter Kang, 04.03.06, 7:00 AM ET

By This Author

Peter Kang
• Eye On Stocks For Monday, April 3, 2006
• Video: Week Ahead: RIM, Radio And Retail
• ViroPharma's Phase II Data 'Introduces Some Uncertainty'
More Headlines

Most Popular Videos


SportsMoney: March Madness A Win For CBS
Fly Me To The Moon
Finding A Gambler's Paradise
Changing China's Currency
Gambling With A Billion

Related Quotes
BIIB 47.10 + 0.00

ENCY 4.89 + 0.00

IDIX 13.57 + 0.00

JNJ 59.22 + 0.00

PFE 24.92 + 0.00






Most Popular Stories


Celebrity Homes
Best-Paid Athletes
Best-Paid Actor and Actresses
Best-Paid Soccer Players
Most Expensive States to Insure Homes



New York - The Amex Pharmaceutical Index (DRG) declined 2.3% for the week, while the Nasdaq Biotechnology Index (NBI) ended a short-term losing streak, ending the week slightly above the unchanged mark.

GlaxoSmithKline (nyse: GSK - news - people ) and Colgate-Palmolive (nyse: CL - news - people ) may be close to submitting separate bids for Pfizer's (nyse: PFE - news - people ) billion-dollar consumer products division, according to recent news reports. Pfizer announced plans last February to sell the division, which raked in $4 billion in sales in 2005 on the strength of such brands as Listerine, Benadryl and Neosporin. A.G. Edwards downplayed the possibility of a bid from Colgate, however. "While clearly coveting the Listerine brand, we believe Colgate would be threatening the 'turnaround' story if it pursued a dilutive large-scale acquisition such as this one, and we don’t think CEO Reuben Mark wants his last 12-15 months as CEO to be marred by questions over Colgate's discipline with capital allocation and decision making, as it was only a few years ago." A.G. Edwards said Johnson & Johnson (nyse: JNJ - news - people ) and Procter & Gamble (nyse: PG - news - people ) have also been named as potential suitors for Pfizer's health care business.

Biogen Idec (nasdaq: BIIB - news - people ) and Elan (nyse: ELN - news - people ) announced on March 29 they enrolled and dosed the first patients in a clinical trial for multiple sclerosis drug Tysabri. The extension study is limited to patients who took part in previous Phase III studies of Tysabri, which was pulled from the market in early 2005 due to safety concerns. Earlier this month, a Food and Drug Administration advisory panel unanimously recommended that the drug be allowed back on the market, but health regulators delayed a decision on the drug to late June. On Friday, research firm Morgan Stanley said Biogen investors preoccupied with Tysabri news may be overlooking potential declines in royalty revenue. "Biogen Idec faces multiple threats to its long-term growth, and we do not believe the market has appropriately valued the long-term downside to this scenario," the firm said. "The most destructive of these occurs if Genentech (nyse: DNA - news - people ) receives approval of a second-generation CD20 antibody, as Biogen Idec’s profit split will decrease by as much as 25% on the entire CD20 franchise." Morgan Stanley reiterated an "equal-weight" rating and $47 price target on Biogen Idec. "While good news on Tysabri may provide some near-term momentum, we increasingly believe the risk to the stock is to the downside."

Shares of Encysive Pharmaceuticals (nasdaq: ENCY - news - people ) plunged 49% last Monday after the FDA delayed approval of Thelin, an experimental treatment for pulmonary arterial hypertension, a lung disease. The FDA said additional clinical trials will need to be conducted for the drug prior to approval, according to Encysive. However, the company said in a statement it will discuss the drug's future with the FDA, and it is "hopeful" the drug will not require further trials. Oppenheimer & Co. downgraded the stock to "neutral" from "buy" on March 27. "In the face of an increasingly competitive marketplace, an approvable letter is not good enough, in our opinion," the research firm said. Oppenheimer expects Myogen (nasdaq: MYOG - news - people ) to file for FDA approval of PAH drug ambrisentan in the fourth quarter of this year. "A central part of our prior investment thesis was that a second-quarter 2006 launch of Thelin would potentially provide a 12- to 18-month head start over Myogen's ambrisentan, which may have a best-in-class product profile," said Oppenheimer. "Now, this time-to-market advantage may be significantly reduced, if not eliminated entirely."

Last Wednesday, Novartis (nyse: NVS - news - people ) exercised an option to co-develop Idenix Pharmaceuticals' (nasdaq: IDIX - news - people ) lead drug candidate, valopicitabine (NM283). Idenix will receive up to $525 million in upfront payments and commercial milestones for the experimental hepatitis C treatment, as well as clinical funding of $300 million or more. Novartis is a majority shareholder of Idenix. ThinkEquity Partners downgraded Idenix to "source of funds" from "accumulate" and sees the commercial potential of the drug as limited. "Given the large stake Novartis has in Idenix, today's move should be viewed as saving face by Novartis first and endorsement of the agent second." The firm also said concerns regarding toxicity at high-dose levels also add to NM283's risk.

[nkelchen]

Antwort auf Beitrag Nr.: 21.051.733 von nkelchen am 03.04.06 13:14:08

Nachschub:
-------------

Inhibitex Reports Top-Line Results in Phase III Study of Veronate(R)
- Company to Host Conference Call Today at 9:00 A.M. EDT -
E-mail | Print | | Disable live quotes Last Update: 6:01 AM ET Apr 3, 2006


ATLANTA, April 3, 2006 /PRNewswire-FirstCall via COMTEX/ -- Inhibitex, Inc. (INHX : inhibitex inc com
News , chart, profile, more
Last: 2.87-4.39-60.49%

1:20pm 04/03/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
INHX2.87, -4.39, -60.5%) today announced that Veronate(R) failed to meet its primary endpoint in the Company's Phase III clinical trial for the prevention of hospital-associated infections due to Staphylococcus aureus (S. aureus) in premature infants weighing between 500 and 1,250 grams at birth. The Company further reported that there were no measurable effects or trends in favor of Veronate for the primary or any of the secondary endpoints.
"The outcome of the trial was unexpected against the background of our preclinical studies and favorable Phase II trends such that additional scrutiny is warranted," stated William D. Johnston, Ph.D., president and chief executive officer of Inhibitex. "We plan to conduct further data analyses and laboratory studies to attempt to reconcile the Phase III data with our prior results. In addition, we will convene a panel of outside experts to review all findings related to the Veronate program. Upon the completion of these assessments, we will determine the appropriate next steps for Veronate. Further, our plans for Aurexis(R) remain unchanged at this time, and we intend to initiate a multi-dose safety and pharmacokinetic study in patients with S. aureus bloodstream infections pending final discussions with the FDA."
The Company also reported that the observed event rate for the primary endpoint was consistent with the assumptions used to design and power the trial. Additionally, there were no significant differences in frequencies of adverse events between the treatment and placebo groups.
The pivotal Phase III trial was a multi-center, placebo controlled, double-blind study comparing the safety and efficacy of Veronate to placebo for the prevention of S. aureus bloodstream infections in premature infants. Infants with birth weights between 500 and 1,250 grams were randomized with equal probability to receive either Veronate (750 mg/kg) or placebo in a series of up to four intravenous infusions administered at intervals over the first two to three weeks of life. The trial enrolled 2,017 infants across 95 neonatal intensive care units across the United States and Canada. Infants were followed for up to 70 days, or until discharge from the hospital.
The primary endpoint of the trial was to demonstrate efficacy in the prevention of hospital-associated bloodstream infections due to S. aureus in these premature infants. Secondary endpoints included a reduction in the frequency of bloodstream infections caused by Candida species (fungi), a reduction in bloodstream infections caused by coagulase-negative staphylococci (CoNS), and a reduction in all-cause mortality.
About Veronate
Veronate, a novel, antibody-based investigational drug being developed to prevent hospital-associated infections in premature infants, is the Company's most advanced product candidate. Veronate has been granted both Fast Track designation and Orphan Drug status by the United States Food and Drug Administration (FDA) and Orphan Medicinal Product (OMP) designation by the European Medicines Agency (EMEA).
Conference Call and Webcast Information
William D. Johnston, Ph.D., president and chief executive officer, and other members of Inhibitex's senior management team will discuss the top-line data via a webcast and conference call today at 9:00 a.m. Eastern Time. To access the conference call, please dial 866-831-6270 (domestic) or 617-213- 8858 (international) five minutes prior to the start time, and provide the access code 86795963. A replay of the call will be available from 11:00 a.m. Eastern Time on April 3, 2006 until 11:59 p.m. Eastern Time on April 10, 2006. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the access code 14636753. A live audio webcast of the call can also be accessed from the Investors section of the Company's website, at http://www.inhibitex.com. An archived webcast of the call will be made available on the Inhibitex website approximately two hours after the event for a period of thirty (30) days.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. All of the Company's drug development programs are based on its proprietary MSCRAMM(R) protein platform. MSCRAMM proteins are found on the surface of pathogenic organisms, and are responsible for the initiation and spread of infections. The Company's most advanced product candidates are Veronate and Aurexis, for which the Company has retained all worldwide rights. The Company's preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines.
For additional information about the Company, please visit http://www.inhibitex.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts in this press release, including statements regarding: the Company's intent to complete further analyses, conduct laboratory studies, consult with outside experts and determine its next steps with respect to the Veronate program and the Company's intent to proceed with a multi-dose study of Aurexis in patients with S. aureus bloodstream infection are forward looking statements. These plans, intentions, expectations or estimates may not actually be achieved and various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including risks related to the Company's ability to: successfully complete further analyses, and assemble a panel of outside experts to assess the Veronate Phase III trial results; obtain regulatory approval from the FDA to advance Aurexis into future clinical trials; obtain, maintain and protect the intellectual property incorporated into its product candidates; the viability of the MSCRAMM platform; obtain funding to support its planned future business activities and other cautionary statements contained elsewhere herein, and in risk factors described in or referred to in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission, or SEC, on March 13, 2006. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.
There may be events in the future that the Company is unable to predict accurately, or over which it has no control. The Company's business, financial condition, results of operations, and prospects may change. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information. The Company qualifies all of the information contained in this press release, and particularly its forward- looking statements, by these cautionary statements.
Inhibitex(R), MSCRAMM(R), Veronate(R), and Aurexis(R) are registered trademarks of Inhibitex, Inc.
CONTACTS:

Inhibitex, Inc.
Russell H. Plumb
Chief Financial Officer
[phone]
[e-mail]

Lilian Stern (Investors)
Stern Investor Relations, Inc.
[phone]
[e-mail]

Kathryn Morris (Media)
KMorrisPR
[phone]
[e-mail]


SOURCE Inhibitex, Inc.
Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc., [phone], [e-mail]; or Investors: Lilian Stern of Stern Investor Relations, Inc., [phone], [e-mail]; or Media: Kathryn Morris, of KMorrisPR, [phone], [e-mail] http://www.prnewswire.com Copyright (C) 2006 PR Newswire. All rights reserved. ********************************************************************** As of Thursday, 03-30-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-24-2006 for INHX @ $7.88. (C) 2006 Comtex News Network, Inc. All rights reserved.

[nkelchen]

Antwort auf Beitrag Nr.: 21.051.733 von nkelchen am 03.04.06 13:14:08

Cortex Announces Clinical Hold on AMPAKINE(R) CX717

E-mail | Print | | Disable live quotes Last Update: 8:20 AM ET Apr 3, 2006


IRVINE, Calif., Apr 03, 2006 (BUSINESS WIRE) -- Cortex Pharmaceuticals, Inc.'s (COR : Cortex Pharmaceuticals Inc
News , chart, profile, more
Last: 2.58-2.67-50.86%

1:17pm 04/03/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
COR2.58, -2.67, -50.9%) , announced that it received a call from the U.S. Food and Drug Administration ("FDA") on the afternoon of Friday, March 31 indicating that the FDA is placing CX717 clinical trials on hold. Cortex should receive formal written notification from the FDA within the next 7-10 days. The action taken by the FDA is related to concerns over some preclinical animal data and not to results from any human clinical trials. Until Cortex receives the formal notification and has had a chance to review its contents, it is unable to describe the exact terms of the notice. Cortex plans to cooperate fully with the FDA and request meetings with the FDA to clarify what must be done to resume clinical testing.
After Cortex receives the written notification from the FDA, has had a chance to analyze its contents, and has had discussions with the appropriate personnel within the agency, it plans to provide an update for shareholders and investors on this issue.
About Cortex Pharmaceuticals
Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer's disease and anxiety disorders. ( http://www.cortexpharm.com/)
Forward-Looking Statement
Note - This press release contains forward-looking statements concerning the Company's research and development activities. The success of such activities depends on a number of factors, including the risks that the Company's proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical test and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease.
SOURCE: Cortex Pharmaceuticals, Inc.
Cortex Pharmaceuticals, Inc. Roger G. Stoll, Ph.D., 949-727-3157 or The Investor Relations Group Damian R. McIntosh / Dian Griesel, Ph.D. 212-825-3210 or Media: Janet Vasquez, 212-825-3210 Copyright Business Wire 2006

[nkelchen]

Antwort auf Beitrag Nr.: 21.058.966 von nkelchen am 03.04.06 19:38:02

Cortex ist ein Amex Wert,
kommt also nicht auf die WL.
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.059.147 von nkelchen am 03.04.06 19:48:43

ich konnte es nicht lassen
und habe mir mal 600Stücke ins Depot gelegt...
(ok - mehr Stücke gibt es nur nach Insiderkäufen)

nk
*es juckte mir einfach in den Fingern*

[nkelchen]

Antwort auf Beitrag Nr.: 21.051.672 von nkelchen am 03.04.06 13:08:49

SCLN-Meldung

dem Markt hat es nicht gefallen -
intraday mehr als 15% Abschlag!
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.059.147 von nkelchen am 03.04.06 19:48:43

Fresenius, Nabi sign transplantation product deal
Tue Apr 4, 2006 3:22 AM ET
FRANKFURT, April 4 (Reuters) - Fresenius AG's (FREG_p.DE: Quote, Profile, Research) biotech unit has signed a deal with Nabi Biopharmaceuticals (NABI.O: Quote, Profile, Research) to advance its transplantation product in the United States, the German healthcare group said on Tuesday.

Fresenius said the deal with Nabi was to advance the clinical development of ATG Fresenius S, a polyclonal antibody to prevent organ graft rejection in organ transplant patients.

FACT BOX

FREG_p.DE (Fresenius)
Last: €147.45
Change: -0.56
Up/Down: -0.38%


AprJulOctJan
Quote
Full Chart
Company Profile
Analyst Research
Fresenius' biotech unit had said in January it would continue the clinical development with another partner after Enzon Pharmaceuticals Inc. (ENZN.O: Quote, Profile, Research) terminated its licensing agreement with Fresenius Biotech. Enzon had decided to redirect its research and development investments.

It said Nabi was granted exclusive sales and distribution rights in North America for up to 15 years following approval by the U.S. Food and Drug Administration.

© Reuters 2006. All Rights Reserved.

[nkelchen]

Antwort auf Beitrag Nr.: 21.068.090 von nkelchen am 04.04.06 14:14:07

Rigel to Present at the BIO 2006 Annual International Convention
Tuesday April 4, 7:30 am ET


SOUTH SAN FRANCISCO, Calif., April 4 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) will present at the BIO 2006 Annual International Convention as part of the BIO Business Forum on Monday, April 10, 2006 at 2:15 p.m. CT at the McCormick Center in Chicago. Raul Rodriguez, Rigel's executive vice president and chief operating officer will discuss Rigel's clinical programs addressing autoimmune diseases and oncology, as well as products currently in pre-clinical development.
ADVERTISEMENT


About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the potential value of Rigel's patent portfolio or its development programs, Rigel's plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy and safety of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects," "believes," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005. Rigel does not undertake any obligation to update forward-looking statements.


Contact: Raul Rodriguez
Phone: [phone]
Email: [e-mail]

Media Contact: Carolyn Bumgardner Wang, WeissComm Partners, Inc.
Phone: [phone]
Email: [e-mail]




--------------------------------------------------------------------------------
Source: Rigel Pharmaceuticals, Inc.

[nkelchen]

Antwort auf Beitrag Nr.: 21.068.090 von nkelchen am 04.04.06 14:14:07

OccuLogix widens focus with purchase
Apr. 5, 2006. 01:00 AM


OccuLogix Inc. says it is acquiring a U.S. company with a new glaucoma treatment, trying to widen the OccuLogix focus on age-related eye ailments after a snag in a key clinical trial.

OccuLogix said yesterday a Phase 3 trial of the Rheo treatment for dry age-related macular degeneration has shown positive results.

But management "believes that it is more likely than not" that the United States Food and Drug Administration will call for further study because the trial covered 115 patients instead of the required 150.

"In light of the possible delay in the U.S. commercial launch of its Rheo system, the company has accelerated its diversification plans, focusing on age-related eye diseases like AMD and glaucoma as they are expected to be the fastest-growing segments of eye care over the next 10 years," OccuLogix said in a statement.

The company has signed a letter of intent to acquire Solx Inc., a private company based at Boston University that "has developed a next-generation system that represents a paradigm shift in the way glaucoma is currently treated."

Financial terms were not disclosed.

Canadian Press

[nkelchen]

Antwort auf Beitrag Nr.: 21.085.480 von nkelchen am 05.04.06 14:13:51

ob ich da in einen Ameisenhaufen gegriffen habe?!

OrthoLogic Announces Management Update

E-mail | Print | | Disable live quotes Last Update: 9:01 AM ET Apr 6, 2006


TEMPE, Ariz., April 6, 2006 /PRNewswire-FirstCall via COMTEX/ -- OrthoLogic Corp. (OLGC : Orthologic Corp
News , chart, profile, more
Last: 1.92-0.04-1.99%

9:54am 04/06/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
OLGC1.92, -0.04, -2.0%) today announced the resignation of James M. Pusey, MD as President and CEO. Dr. Pusey has decided to pursue other opportunities.
John M. Holliman, III, a director of OrthoLogic since September 1987 and Chairman of the Board of Directors since August 1997, will assume the title of Executive Chairman and will lead the Company's business and corporate strategic activities.
Randolph C. Steer, MD, Ph.D. has been named President of OrthoLogic, directing the Company's strategy and operations in all clinical development and regulatory areas.
Dr. Steer has been an independent pharmaceutical, biotechnology and medical devices consultant since 1989, and has provided consulting services to OrthoLogic since 2002. He has a broad scientific, medical and business background, including extensive experience in pre-clinical, clinical and regulatory affairs, having held key management positions in leading corporations and having served as an advisor to many companies in the United States and abroad. In addition, he serves as an active member of the board of directors of public and private corporations. Dr. Steer has also advised numerous venture capital firms, investment banks and independent investors on the commercial development of drugs, biologics, diagnostics and medical devices. He has served as Associate Director of Medical Affairs at Marion Laboratories; Medical Director at Ciba Consumer Pharmaceuticals (Ciba-Geigy Corporation); Vice President, Senior Vice President and Member of the Executive Committee at Physicians World Communications Group; Chairman, President and Chief Executive Officer of Advanced Therapeutics Communications International, a global drug regulatory group, and Chairman and Chief Executive Officer of Vicus.com, Inc. He is a member of the Board of Directors of several companies, including Techne Corporation and BioCryst Pharmaceuticals. Dr. Steer received his MD degree from the Mayo Medical School and his Ph.D. from the University of Minnesota, where he also completed a residency and subspecialty fellowship in clinical and chemical pathology. He is a Fellow of the American College of Clinical Pharmacology.
About OrthoLogic
OrthoLogic is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served conditions. The Company is focused on the development and commercialization of two product platforms: Chrysalin(R) (TP508) and AZX100.
Chrysalin, the Company's novel synthetic peptide, is being studied in two lead indications, both of which represent areas of significant unmet medical need -- fracture repair and diabetic foot ulcer healing. Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become a leading company focused on tissue and bone repair. The Company owns exclusive worldwide rights to Chrysalin.
AZX100 is a novel pre-clinical 24-amino acid peptide, the first of a new class of compounds in the field of smooth muscle relaxation called Intracellular Actin Relaxing Molecules, or ICARMs(TM). AZX100 is currently being evaluated for medically and commercially significant applications, such as the treatment of vasospasm associated with subarachnoid hemorrhage, the prevention of keloid scarring and the treatment of asthma. OrthoLogic has an exclusive worldwide license to AZX100.
OrthoLogic's corporate headquarters are in Tempe, Arizona. For more information, please visit the Company's Web site: www.orthologic.com.
Statements in this press release or otherwise attributable to OrthoLogic regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which include the timing and acceptability of FDA filings and the efficacy and marketability of potential products, involve risks and uncertainties that could cause actual results to differ materially from predicted results. These risks include: delays in obtaining or inability to obtain FDA, institutional review board or other regulatory approvals of preclinical or clinical testing; unfavorable outcomes in our preclinical and clinical testing; the development by others of competing technologies and therapeutics that may have greater efficacy or lower cost; delays in obtaining or inability to obtain FDA or other necessary regulatory approval of our products; our inability to successfully and cost effectively develop or outsource manufacturing and marketing of any products we are able to bring to market; changes in FDA or other regulations that affect our ability to obtain regulatory approval of our products, increase our manufacturing costs or limit our ability to market our products; our possible need for additional capital in the future to fund the continued development of our product candidates; and other factors discussed in our Form 10-K for the fiscal year ended December 31, 2005, and other documents we file with the Securities and Exchange Commission.
SOURCE OrthoLogic Corp.
investors, Melanie Friedman of Stern Investor Relations, Inc., [phone], [e-mail], for OrthoLogic Corp. http://www.prnewswire.com Copyright (C) 2006 PR Newswire. All rights reserved. ********************************************************************** As of Sunday, 04-02-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-15-2006 for OLGC @ $2.70. (C) 2006 Comtex News Network, Inc. All rights reserved

[nort.]

NABI entwickelt sich sehr passabel...

Kursziel sollte bei 8$ erstmal liegen. Danach sollte sich das fasttrack für NicVax (Impfstoff gegen Nikotinsucht) im Kurs auszeichnen...

[nkelchen]

Depot und Index in der Konsi..
Neuaufnahme OLGC etwas vorschnell -
die Strafe sind -12%


Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:


Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Cash:1317$-1080€ (Depotgewinne, die realisiert wurden)

Im Depot:
400 SCLN
250 NABI
250 PCYC
225 RIGL
800 OGLC
200 AGEN
Kapitaleinsatz:5460€
Wert:6903€
Entwicklung:26,50%

aktueller Gesamtwert:7983€
Entwicklung:46%

Watchlist: RHEO/AGEN/ENCY

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
\\'zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Insiderkäufe nach dem draw down, sind für eine
Depotaufnahme unablässig.

nk

[Mannitrader]

Hallo!!
Also ich finde deinen Thread echt super und bin echt begeistert..
Bei Nabi bin ich auch nämlich investiert und den Kursverlauf seit dem Absturz läuft blendend...

Ich habe den Wert Antigenics ins Watchliste eingesetzt, du hast ja jeden Wert, die du im Depot hast genau analysiert...Nur Antigenics nicht..

Ich habe leider keine Insiderkäufe bei Antigenics gefunden oder warum hast du den Wert ins Depot genommen...Für eine genauere Begründung wäre ich dankbar...

Orthologic will auch kaufen, aber ich werde noch bißschen abwarten....läuft echt nicht gut..

Gruß Mannitrader

[nkelchen]

Antwort auf Beitrag Nr.: 21.137.652 von Mannitrader am 09.04.06 21:00:34

Hallo Manni,
freue mich über deinen Besuch.
Habe gerade Antigenix wieder zum Einstand aus dem Depot entfernt.
Ich war einfach zappelig und wollte endlich mal wieder neue Werte im Depot haben.
Es gab aber (noch) keine Insiderkäufe und somit habe ich auch bei OLGC gegen meine Regel verstossen.
(ich bin halt manchmal zu ungeduldig und zu verspielt)

RHEO ist vom Gap her am aufregendsten
(heute schon wieder minus 1x.xx%)
da gab es im Vorfeld des crash jede Menge Insiderverkäufe,
sogar danach bei 5,xx noch einmal.
Wenn da mal was positives kommen würde.....
Nun denn, abwarten ist angesagt -
man kann es nicht zwingen!

Gruss
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.151.741 von nkelchen am 10.04.06 21:17:37

hier steht eine Entscheidung an -
raus aus der Range und Fortsetzung des rebounds,
oder Rückfall in den downtrend...
Umsätze sind ca. 3-4mal höher, als noch vor Tagen und Wochen.

ein SK über 4,60 muss her!
nk

[nkelchen]

Junge, Junge -
irgendwie ist Biotech zur Zeit out!

Gibt es vielleicht schon etwas Neues, wovon ich noch nichts weiß?
Ich stöbere mal durch`s Board...

nk

[nkelchen]

Pharmacyclics Buys Celera Compounds For Up To $150M



By Karen Pihl-Carey

http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher…

Staff Writer
Three months after announcing a restructuring plan to focus only on molecular diagnostics and proteomics, Celera Genomics Group sold several small-molecule drug candidates to Pharmacyclics Inc. in a deal worth up to $150 million in up-front, equity and milestone payments.

"We just had a lot of things that were going on," said David Speechly, Celera's senior director of investor relations and corporate communications, who added that the company was happy with the progress of each program but wanted to focus on "our highest-growth opportunities."

In January, Rockville, Md.-based Celera made the decision to sell its therapeutic products.

The deal with Pharmacyclics, of Sunnyvale, Calif., includes an HDAC inhibitor in Phase I trials for refractory solid tumors; an HDAC-8 selective inhibitor in preclinical development to treat cancer; a Factor VIIa inhibitor targeting a tumor signaling pathway involved in angiogenesis, tumor cell growth and metastases, and with potential applications in anticoagulation and cardiology; and B-cell-associated tyrosine kinase inhibitors that could be used in lymphoma and autoimmune diseases, such as rheumatoid arthritis.

Pharmacyclics made the acquisition "to acquire a deep pipeline of novel oncology products," said Geoff Cooper, the company's senior vice president of business development.


Terms of the agreement include a $2 million up-front cash payment and an equity payment of between 500,000 shares and 1 million shares of Pharmacyclics, worth between $2.3 million and $4.6 million. The company's stock (NASDAQ:PCYC) rose 11 cents on Monday, to close at $4.61.

[Mannitrader]

Hallo!!
Da bin ich mal wieder.
Gut, dass ich Student bin, da kann ich auch bißschen English.
Also, dass hat sich schon mal positiv gelesen.
Bin heute bei Pharmacyclics eingestiegen, hoffe,dass ich richtig gemacht habe.

Nabi werde ich warscheinlich in den nächste Tagen verkaufen, da ich etwas Cash brauche für etwas neues.(Bin bei 3,18 dabei)
Will ja auch nicht zuviel Gewichtung von Biotechs haben, da moment wieder ruhiger geworden ist.

Also, hier werde ich öfters vorbeischauen und verfolgen was hier für Infos kommen...Da erpare ich mir das sucherei, da hier schön angegeben ist...

Gruß Manntrader

[nkelchen]

Antwort auf Beitrag Nr.: 21.168.293 von Mannitrader am 11.04.06 23:03:25

Wird schon was werden, mit PCYC!
(hoffentlich)

NEWS:


TLC Vision reduces stake in OccuLogix
Apr. 11, 2006. 06:20 PM
CANADIAN PRESS


ST. LOUIS, Mo. — TLC Vision Corp. (TSX: TLC), whose main business is providing doctors with the tools for providing eye care for their patients, has reduced its ownership stake in battered subsidiary OccuLogix Inc. to 49 per cent.

TLC Vision said Tuesday it reduced its stake in Toronto-based OccuLogix (TSX: RHE) below 50 per cent so it no longer would be required to consolidate the subsidiary's financial results with its own.

OccuLogix, which is developing a blood-filtration system for treating a form of age-related blindness, had a 2005 net loss of $163 million (U.S.), mostly due to a big writedown that followed puzzling results from a clinical trial of its Rheo system.

Shares of both companies plunged in early February after OccuLogix announced that one of its two Phase 3 trials of Rheo had failed to show the group of patients who got the treatment did statistically better than the patients who didn't.

Since then, OccuLogix has said further analysis suggests that Rheo actually works better than anticipated but the untreated group did much better than it should have, in part, because of flaws in the patient-selection process.

TLC Vision Corp.'s sell-off of 800,000 OccuLogix shares accounted for the bulk of the stock's trading Tuesday at the Toronto Stock Exchange. OccuLogix shares closed at $3.12 Cdn, down 22 cents from the previous close and down 78 per cent from its Feb. 2 close of $14.55 prior to the release of the clinical results.

TLC Vision shares closed at $7.20 Cdn in Toronto, down 10 cents from the previous day, and at $6.32 (U.S.), down six cents, on Nasdaq where a higher volume is traded. It's stock closed at $7.93 (U.S.) on Nasdaq on Feb. 2.

[nkelchen]

Antwort auf Beitrag Nr.: 21.175.887 von nkelchen am 12.04.06 15:04:27

http://webwire.com/ViewPressRel.asp?SESSIONID=&aId=12528

CybeRelease: Alternative Energy Sector Plugs in Big Gains

CybeRelease
4/12/2006 8:56:26 AM

WebWire Related Industries
• Banking/Financial Services
• Financial Markets
• OTC/SmallCap
(CybeRelease, April 12, 2006) - Lake Harmony, PA - WSTRP Power Plays - Norilsk Nickel, the world’s largest producer of nickel and palladium, electrified followers of alternative energy stocks by investing, announced by Plug Power Inc (NASDAQ: PLUG) to be, a total of $217 million cash from the Russian firm. Share price and volume of Plug skyrocketed on the investment news, to close at $5.98, up 1.10 (+22.54%) on 28,551,249 shares.


The announcement continues to keep companies in this sector in the spotlight and helped to lift the sector. Neah Power Systems Inc (OTC: NPWS) closed at $1.29, up 0.24 (+22.86%) on 352,771 shares. Fuelcell Energy Inc (NASDAQ: FCEL) at $11.51, up 0.46 (+4.16%) on 825,825 shares. Ballard Power (NASDAQ: BLDP) at $7.62, up 0.13 (+1.74%) on 792,840 shares. Hoku Scientific (NASDAQ: HOKU) at $5.9999, up 0.0699 (+1.18%) on 333,038 shares. Medis Technologies Ltd (NASDAQ: MDTL) at $21.78, up 0.01 (+0.05%) on 268,148 shares.




NEAH Power, based in Bothell, Washington, is the most recent addition to the public market and looks like a tremendous value play. It also has a notable investor list, which includes Intel Capital, Intel’s (NASDAQ: INTC) strategic investment program, Frazier Technology Ventures, Alta Partners, Castile Ventures and WestAm, the global investment management arm of Germany’s fourth largest bank, by assets, WestLB AG.




For more information, go to http://www.CybeRelease.com/wstrp41206.htm


CybeRelease Gainers are Spherix Incorporated (Nasdaq: SPEX), InPhonic, Inc. (Nasdaq: INPC), Columbia Sportswear Company (Nasdaq: COLM), etrials Worldwide, Inc. (Nasdaq: ETWC) and Secure Computing Corporation (Nasdaq: SCUR).


CybeRelease Decliners are Authentidate Holding Corp. (Nasdaq: ADAT), CAS Medical Systems, Inc. (Nasdaq: CASM), Micro Linear Corporation (Nasdaq: MLIN), Fuel-Tech, N.V. (Nasdaq: FTEK) and SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN).


Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $595.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.






Related Links

CybeRelease.com
www.CybeRelease.com







Contact Information:
C. P. Barry
Media Contact
CybeRelease
1.888.478.7669
[e-mail]

[nkelchen]

Antwort auf Beitrag Nr.: 21.175.887 von nkelchen am 12.04.06 15:04:27

:look

http://pittsburgh.dbusinessnews.com/shownews.php?newsid=7041…

Black Dragon Resources (OTC: BDGR) Gets Featured Report From OTCReporter.com
Pittsburgh -
( CybeRelease, April 11, 2006 ) - Lake Harmony, PA - OTCReporter.com's "Featured Company", Black Dragon Resources (OTC PK: BDGR) recently announced major revenue increase news.

Black Dragon Resource Companies, Inc. (BDGR) announced that it expects its sales for the fourth quarter ended December 31, 2005, on an unedited basis to be approximately $709,000, up almost 26% over the previous quarter. Sales for the 2005 fiscal year end December 31 are expected to total approximately $1.655 million. The revenues for the year increased sequentially during the year; $421,000 for the first and second quarter combined; $525,000 for the third quarter and $709,000 for the fourth quarter. The Company expects revenues for the first quarter 2006 to approach $1 million, a record quarter for the Company and an increase of over 41% from the last quarter of 2005.

For a Free Newsletter and more information, go to www.OTCReporter.com

CybeRelease Gainers are Capstone Turbine Corporation (Nasdaq: CPST), Superior Well Services, Inc. (Nasdaq: SWSI), Isramco, Inc. (Nasdaq: ISRL), RF Monolithics, Inc. (Nasdaq: RFMI), Elbit Medical Imaging Ltd. (Nasdaq: EMITF), 1-800 FLOWERS.COM, Inc. (Nasdaq: FLWS), Pacific Ethanol, Inc. (Nasdaq: PEIX) and BE Semiconductor Industries NV (Nasdaq: BESI).

CybeRelease Decliners are Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Inhibitex, Inc. (Nasdaq: INHX), Broadwing Corporation (Nasdaq: BWNG), Neoware, Inc. (Nasdaq: NWRE), Cyberonics, Inc. (Nasdaq: CYBX), InterDigital Communications Corp. (Nasdaq: IDCC), Intevac, Inc. (Nasdaq: IVAC) and Alliance Fiber Optic Products, Inc. (Nasdaq: AFOP).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $595.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.

Contact:
C. P. Barry
Company: CybeRelease
Phone: [phone]
Source: CybeRelease.com

Posted on:
Tuesday, April 11, 2006 04:04 AM

[jeo1]

Liebe Bordmitglieder,

werde heute meine Nabi Aktien gewinnbringend verkaufen (Einstiegskurs 3,16 Dollar) und in Inhibitex (INHX) einsteigen. Heute ist der letzte Handelstag an dem ich vor Ostern handeln kann. Diese Chance lasse ich mir nicht entgehen. In den letzten Tagen ist die Aktie von 8 auf 2 Dollar gefallen und das völlig übertrieben.

Das Medikament befindet sich in Testphase drei. Es wurde bekannt gegeben, dass ein Test fehlgeschlagen ist. Schuld war aber nicht das Medikament sondern die Testart. In anderen Tests lieferte das Medikament signifikante Ergebnisse. Wenn Inhibitex im Tagesverlauf unter grossem Volumen auf 1,50 Dollar sinkt, so wie ich vermute, werde ich mein Glück versuchen.

[nkelchen]

Antwort auf Beitrag Nr.: 21.188.867 von jeo1 am 13.04.06 11:36:02

Hallo Jeo,
habe das Teil auch auf meiner WL.
Aber Achtung, es sind erst 8Handelstage nach drawdown vergangen
und eine Bodenbildung, im Chart nicht zu erkennen.
Warte mal lieber die Ostertage ab...
Gruss
nk

NEWS
______


SciClone to Report First Quarter 2006 Results on May 3, 2006
SAN MATEO, CA -- (MARKET WIRE) -- 04/13/2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2006 results and host a conference call on Wednesday, May 3, 2006.

The conference call will contain forward-looking statements. Financial and statistical information to be discussed on the call will be posted on the Investor Relations section of SciClone's web site at www.sciclone.com prior to the commencement of the conference call.


DATE: Wednesday, May 3, 2006

TIME: 11:30 a.m. ET (8:30 a.m. PT)

WEBCAST: Live call and replay accessible at www.sciclone.com

LIVE CALL: 800-817-4887 (U.S./Canada)
913-981-4913 (international)

REPLAY: 888-203-1112 (U.S./Canada)
719-457-0820 (international)
Passcode: 2871842
(Available from 2:30 p.m. ET on May 3, 2006 through
12:00 a.m. ET on May 17, 2006)

About SciClone
SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products to market in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.






--------------------------------------------------------------------------------


Corporate information contact:
Becky Horner
Investor Relations
SciClone Pharmaceuticals, Inc.
650-358-3437


SOURCE: SciClone Pharmaceuticals, I

[nkelchen]

AGEN heute 1.Posi 300 Stück zu 2,36 ins Depot.
(sind immerhin 10% weniger Kosten, als vor einer Woche)

Bei RHEO juckt es mich in den Fingern...
..mal sehen...

nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.195.203 von nkelchen am 13.04.06 17:07:39

Mit 5$ über die Ostertage?!


nk

[nkelchen]

RIGEL Konsi beendet!?
11,xx$ wäre da ein nötiger SK.


nk

[jeo1]

Hallo nkelchen,

danke für den Tip! Du hast anscheinend auch Probleme eine Bodenbildung abzuwarten (siehe Agen). Im übrigen finde ich, dass Inhibitex(INHX) besser bewertet ist als Agen. Agens Schulden sind mir ein wenig hoch mit über 50 Mio Dollar. Wenn die magische 2 Dollar Grenze hält, sollte Inhibitex bald wieder andere Höhen sehen.

Gruss jeo

[nkelchen]

Antwort auf Beitrag Nr.: 21.197.005 von jeo1 am 13.04.06 18:47:48

Ja Jeo,
manchmal besiegt bei mir das Gefühl den Verstand!
(wäre sonst aber auch alles zu eintönig, oder..)

Was hälst Du denn von RHEO?

Gruss und schöne Feiertage
nk

[jeo1]

Klar ist, das Rheo auf dem "Markt des Alterns" im Moment noch grosse Potentiale hat. Bin aber der Meinung, dass in Zukunft Rheos Produkte durch Medikamente ersetzt werden können. Im Moment setze ich auf Sequenom, Genelogic, Nabi, Praecis, Avigen, Nymox, Inhibitex, Vaso Medical und Inex Pharma sowie auch Cell Therapeutics, wo die Zulassung von Xyotax nur noch eine Frage der Zeit ist.

Ausserhalb des Biotechsektors bin ich seit November investiert in Covad Communications, die den US DSL Markt als Netzanbieter "rulen" und sich bereits fast vervierfacht haben.

Ansonsten ist Vaso Medical interessant. Diese haben ein Ultraschallverfahren entwickelt und zugelassen, welches es ermöglicht die Herzkranzgefässe zu erweitern und eine Bypassoperation zu verhindern, welche mit dem öffnen des Brustkorbes einhergeht. So ist es möglich Herzkranzverschlüsse ohne grosse Nebenwirkungen zu heilen. Ganz interessant für Ältere Menschen! In Deutschland und den USA wird das Verfahren bereits angewendet. Vaso wurde in einigen US Foren durch eine kriminelle Bande in Verruf gebracht. Wie sich herausstellte waren es zwei Leute einer New Yorker Investmentfirma, die die Kurse beeinflussen wollten.

Viel Spass beim Traden und Frohe Ostern wünscht jeo!

[nkelchen]

Antwort auf Beitrag Nr.: 21.199.386 von jeo1 am 13.04.06 21:51:46

FROHE OSTERN



eine turbulente Woche ist vorbei.
Konsolidierung aller Orten, so auch in meinem Deot.
2.Versuch AGEN..1.Posi zu 2,36
mit OLGC war ich zu voreilig...


Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:


Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Cash:1317$-1080€ (Depotgewinne, die realisiert wurden)

Im Depot:
400 SCLN
250 NABI
250 PCYC
225 RIGL
800 OGLC
300 AGEN
Kapitaleinsatz:5610€
Wert:6983€
Entwicklung:24,50%

aktueller Gesamtwert:8063€
Entwicklung:43,70%

Watchlist: RHEO//ENCY/INHX

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
\\\'zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Insiderkäufe nach dem draw down, sind für eine
Depotaufnahme unablässig.
(Ausnahmen bestätigen die Regel..hüstel..grins..)
nk

Gruss
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.201.282 von nkelchen am 14.04.06 10:07:02

-Insiderkäufe nach dem draw down, sind für eine
Depotaufnahme unablässig.
(Ausnahmen bestätigen die Regel..hüstel..grins..)


Das wollte ich so, dann doch nicht stehen lassen!

Also:
grundsätzlich hebe ich den Einkaufswert um ca. 50%an.

Neuaufnahme mit Insiderkauf ca. 2500$
Neuaufnahme ohne Insiderkauf ca. 1250$

reduziere darum auch meine OLGC um 200 auf 600 Stück
und verbuche/realisiere einen Verlust von 70$.

So habe ich wieder Ordnung in meinen Depotkriterien
Ob es allerdings gute Kriterien sind...

nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.213.344 von nkelchen am 17.04.06 15:51:25

Kauf RHEO 200Stück zu 3,16$
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.213.440 von nkelchen am 17.04.06 15:58:06

http://online.barrons.com/google_login.html?url=http%3A%2F%2…

es geht um ENCY -
mehr weiss ich leider nicht...
nk

[nkelchen]

bizjournals.com
Nabi credit rating cut by S&P
Friday April 14, 12:38 pm ET


Nabi Biopharmaceuticals' credit rating was lowered this week by Standard & Poor's because analysts are concerned about the company's future prospects.
S&P lowered its rating on Nabi (NASDAQ:NABI - News), which has facilities in Rockville and Boca Raton, Fla., to B- from B. The rating outlook is negative.

ADVERTISEMENT


"The downgrade reflects our belief that despite the company's recent announcement that it is resuming development of its previously derailed lead pipeline product, StaphVAX (a vaccine against staph infections), Nabi continues to face a number of major uncertainties and has very limited cash flow generating prospects," says S&P analyst Arthur Wong.

The lower rating reflects Nabi's narrow business focus, lack of sales diversity and uncertain pipeline.

Nabi is developing drugs mainly for infectious diseases and autoimmune disorders. Its lead product, StaphVAX, failed in a second round of Phase III clinical trials last fall. Nabi will move forward with development of the vaccine, though it plans to seek a partner to help fund clinical development.

The biopharmaceutical company currently markets several products that generate modest revenue.

StaphVAX was thought by many analysts and industry observers to be a potential blockbuster product eventually amassing hundreds of millions of dollars in annual sales. News that the vaccine failed in late-stage tests shocked many in the biomedical community and caused Nabi's stock to plummet about 70 percent in one day.

Nabi is working to boost its pipeline should StaphVAX not succeed. The company earlier this month acquired from Fresenius Biotech the exclusive sales and distribution rights to a drug in late-stage development for the prevention and treatment of rejection following organ transplantation. Fresenius, part of a German-based health care giant, currently markets the drug in more than 60 countries worldwide, but not in the United States.

Nabi assumes oversight of an ongoing Phase III clinical study that is being conducted in lung transplant patients in the United States and Europe. Assuming all milestones are met, Nabi expects to file an application requesting U.S. market approval for the drug in early 2009

Published April 14, 2006 by the Washington Business Journal

[nkelchen]

Antwort auf Beitrag Nr.: 21.213.841 von nkelchen am 17.04.06 16:27:22

http://biz.yahoo.com/cc/8/67678.html

Nabi Biopharmaceuticals Earnings Conference Call (Q1 2006)
Scheduled to start Wed, Apr 26, 2006, 4:30 pm Eastern
Check back at the scheduled start time for
the audio link to appear in this spot.
Add This Event To Your Yahoo! Calendar




After the event has finished, the audio will be available
from this page until Fri, Apr 27, 2007





About Nabi Biopharmaceuticals (NasdaqNM:NABI)

Nabi Biopharmaceuticals engages in the development and marketing of products for Gram-positive bacterial infections, hepatitis, kidney disease, and nicotine addiction. The company markets its Nabi-HB for the postexposure prevention of hepatitis B infection; Aloprim for the treatment of chemotherapy-induced hyperuricemia; and PhosLo for the treatment of hyperphosphatemia in end-stage renal failure patients primarily in the United States. It is also developing Nabi-HB for prevention of reinfection with hepatitis B in HBV-positive liver transplant patients; PhosLo, a Phase IIIb clinical trial product, for the treatment of hyperphosphatemia in predialysis chronic kidney disease patients. Nabi Biopharmaceuticals’ products in clinical development include vaccines and antibody-based therapies, under phase-II clinical trail plans, for healthcare associated and community acquired S. aureus and S. epidermidis infections; Civacir, under pahse-II clinical trail plans, for preventing reinfection with hepatitis C disease in liver transplant patients; and NicVAX, a phase-II clinical trail product, for the treatment of nicotine addiction. The company has strategic alliances principally with Public Health Services/National Institute of Health for processes to manufacture vaccines against staphylococcal infections, including StaphVAX; and Chiron Corporation for four vaccines, including the vaccine for hepatitis C that would be used in the development of Civacir. Nabi Biopharmaceuticals sells its biopharmaceutical products to wholesalers, distributors, hospitals, and home healthcare companies, as well as antibody products to pharmaceutical and diagnostic product manufacturers. The company was founded in 1967 and is based in Boca Raton, Florida.

[nort.]

nkelchen, schon INHX angesehen?

[nkelchen]

Antwort auf Beitrag Nr.: 21.238.243 von nort. am 19.04.06 13:07:10

logo -
ist auf der Watchlist.
Ein paar Tage warte ich noch ab.

Gruss
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.238.422 von nkelchen am 19.04.06 13:17:46

http://biz.yahoo.com/prnews/060419/sfw022.html?.v=54

Press Release Source: Rigel Pharmaceuticals, Inc.


Rigel Announces Presentations at Two Investor Conferences
Wednesday April 19, 7:30 am ET


SOUTH SAN FRANCISCO, Calif., April 19 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that James M. Gower, Chairman and Chief Executive Officer will provide a company overview at two upcoming investor conferences:

6th Annual Fortis Bank Biotechnology Conference
Four Seasons Hotel, Park Lane, London
Wednesday, April 26
3:30 p.m. GMT

Deutsche Bank 2006 Health Care Conference
Sheraton Boston Hotel in Boston, MA
Wednesday, May 3
1:45 p.m. EDT
*Will be webcast

To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com/rigel/events. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to, Rigel's plans to pursue pre-clinical and clinical development of product candidates and the timing thereof and the potential efficacy and safety of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects," "believes," and similar expressions are intended to identify these forward- looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward- looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005. Rigel does not undertake any obligation to update forward-looking statements.


Contact: Raul Rodriguez
Phone: [phone]
Email: [e-mail]

Media Contact: Carolyn Bumgardner Wang, WeissComm Partners, Inc.
Phone: [phone]
Email: [e-mail]




--------------------------------------------------------------------------------
Source: Rigel Pharmaceuticals, Inc.

[nkelchen]

Antwort auf Beitrag Nr.: 21.239.323 von nkelchen am 19.04.06 14:29:08

NABI
Share Related Items
Market Cap: $ 347.58M
Shares Out: 59.52M


March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
NABI Nabi Biopharmaceuticals - Common Stock 4,466,900 1.60 1,729,870 2.58


February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
NABI Nabi Biopharmaceuticals - Common Stock 4,396,767 (27.18) 2,067,591 2.13


January 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
NABI Nabi Biopharmaceuticals - Common Stock 6,037,931 (7.56) 1,428,828 4.23


December 2005
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
NABI Nabi Biopharmaceuticals - Common Stock 6,531,994 (14.11) 2,856,533 2.29

mfG
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.261.382 von nkelchen am 20.04.06 20:13:11

SCLN
Share Related Items
Market Cap: $ 145.04M
Shares Out: 45.90M

March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
SCLN SciClone Pharmaceuticals, Inc. - Common Stock 1,066,763 17.10 313,027 3.41

February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
SCLN SciClone Pharmaceuticals, Inc. - Common Stock 910,956 6.01 281,711 3.23

January 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
SCLN SciClone Pharmaceuticals, Inc. - Common Stock 859,325 (74.31) 850,330 1.01

December 2005
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
SCLN SciClone Pharmaceuticals, Inc. - Common Stock 3,345,167 58.60 833,471 4.01

[nkelchen]

Antwort auf Beitrag Nr.: 21.261.382 von nkelchen am 20.04.06 20:13:11

Share Related Items
Market Cap: $ 89.57M
Shares Out: 19.90M


March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
PCYC Pharmacyclics, Inc. - Common Stock 2,041,707 (13.50) 128,987 15.83

February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
PCYC Pharmacyclics, Inc. - Common Stock 2,360,302 (7.47) 282,606 8.35

January 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
PCYC Pharmacyclics, Inc. - Common Stock 2,550,928 (67.49) 1,762,899 1.45

December 2005
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
PCYC Pharmacyclics, Inc. - Common Stock 7,846,610 47.77 473,633 16.57

[nkelchen]

Antwort auf Beitrag Nr.: 21.261.382 von nkelchen am 20.04.06 20:13:11

RIGL
Share Related Items
Market Cap: $ 272.98M
Shares Out: 24.82M


March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RIGL Rigel Pharmaceuticals, Inc. - Common Stock 2,457,115 1.45 479,361 5.13

February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RIGL Rigel Pharmaceuticals, Inc. - Common Stock 2,421,886 (10.04) 399,742 6.06

January 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RIGL Rigel Pharmaceuticals, Inc. - Common Stock 2,692,040 (23.12) 643,387 4.18

December 2005
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RIGL Rigel Pharmaceuticals, Inc. - Common Stock 3,501,788 146.09 2,775,804 1.26

[nkelchen]

Antwort auf Beitrag Nr.: 21.261.382 von nkelchen am 20.04.06 20:13:11

OLGC
Share Related Items
Market Cap: $ 74.24M
Shares Out: 40.35M


March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
OLGC Orthologic Corp. - Common Stock 1,081,867 261.75 934,339 1.16

February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
OLGC Orthologic Corp. - Common Stock 299,066 51.92 124,480 2.40

[nkelchen]

Antwort auf Beitrag Nr.: 21.261.382 von nkelchen am 20.04.06 20:13:11

INHX
Share Related Items
Market Cap: $ 74.10M
Shares Out: 30.24M


March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
INHX Inhibitex, Inc. - Common Stock 1,599,588 64.76 160,271 9.98

February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
INHX Inhibitex, Inc. - Common Stock 970,837 7.85 126,675 7.66

[nkelchen]

Antwort auf Beitrag Nr.: 21.261.382 von nkelchen am 20.04.06 20:13:11

AGEN
Market Cap: $ 108.66M
Shares Out: 45.66M


March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
AGEN Antigenics Inc. - Common Stock 8,932,050 10.60 550,734 16.22

February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
AGEN Antigenics Inc. - Common Stock 8,076,150 (0.50) 291,017 27.75

January 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
AGEN Antigenics Inc. - Common Stock 8,116,837 1.12 292,405 27.76

[nkelchen]

Antwort auf Beitrag Nr.: 21.261.382 von nkelchen am 20.04.06 20:13:11

RHEO
Share Related Items
Market Cap: $ 138.78M
Shares Out: 42.18M


March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RHEO OccuLogix, Inc. - Common Stock 7,009,989 16.99 1,292,676 5.42

February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RHEO OccuLogix, Inc. - Common Stock 5,991,831 58.68 2,208,297 2.71

January 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RHEO OccuLogix, Inc. - Common Stock 3,776,003 18.31 698,466 5.41

[nkelchen]

http://www.palmbeachpost.com/business/content/business/epape…

Investors demand Nabi sell
By Stephen Pounds

Palm Beach Post Staff Writer

Friday, April 21, 2006

Two major investors are asking Nabi Biopharmaceuticals to sell the company as a way to recoup shareholder losses.

In the past three days, two New York-based investment firms, Knott Partners Management LLC and Third Point LLC, have criticized the Boca Raton-based drugmaker for its poor performance and questioned its strategy in documents filed with the U.S. Securities and Exchange Commission.

More business news
• Latest news, columnists
• Local stocks
• Market tools
• Mortgage rates
• Gas prices


Together, the investment firms hold 10.2 million shares of Nabi, or 18 percent of the company's stock.

A Nabi spokesman said the company "listens to all the recommendations from all our shareholders" but declined to say if Chief Executive Tom McLain and Nabi's board are considering a sale.

Investor demands to sell the company come less than six months after the company's experimental vaccine for staph infections, StaphVAX, failed in large-scale trials. Since then, Nabi (Nasdaq: NABI) shares have dipped by more than half, from a high for the past year of $15.82 a share to Thursday's closing price of $6.51.

Nabi investors are pulling no punches.

In an SEC document filed Wednesday, Anthony Campbell, a Knott general partner, said he met with Nabi executives three times in the past month over its strategy of experimental drug development in the face of mounting losses and a stagnant stock price.

"The company has on numerous occasions missed revenue projections and scientific milestones," Campbell's letter said. "The shareholders of Nabi have suffered enough."

On Monday, Third Point Chief Executive Daniel Loeb voiced similar concerns, objecting to what he called Nabi's inability "or unwillingness" to forecast a time frame for positive cash flow and earnings.

Loeb has told executives since February that management should consider a sale "in a process conducted as publicly as possible," suggesting an auction. He also asked that Nabi refrain from selling any drugs under development or partnering with another firm, said documents filed with the SEC.

McLain was unavailable for comment Thursday. But Nabi Vice President Tom Rathjen denied the company had ignored overtures from other firms.

Rathjen declined to confirm if companies have approached Nabi and wouldn't say if McLain or Nabi's board was considering a sale. He defended Nabi's strategy, saying drug development is a lengthy process.

"We do these studies in various phases. We submit that data and the (Food and Drug Administration) reviews it. It's impossible to predict precisely when products will come to market," Rathjen said.

Shares in Nabi jumped after Monday's SEC filing but fell Thursday after the Knott filing accused management of ignoring overtures for Nabi.

"The gains that you saw earlier came after the Third Point filing said they might sell, and people bought into it," said analyst Dallas Webb of Sanford Group in Boca Raton. "The second filing probably worried (investors) a bit, after someone accused them of ignoring a (potential) buyer of the company."

Still, Nabi should explore a sale, Webb said: "Their drugs in the pipeline aren't near reaching the market and the drugs that are on the market won't generate the cash flow needed."

[nkelchen]

Antwort auf Beitrag Nr.: 21.267.751 von nkelchen am 21.04.06 10:25:08

http://www.prnewswire.com/cgi-bin/stories.pl?
ACCT=104&STORY=/www/story/04-20-2006/0004343679&EDATE=" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/cgi-bin/stories.pl?
ACCT=104&STORY=/www/story/04-20-2006/0004343679&EDATE=

HOUSTON, April 20 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals
(Nasdaq: ENCY) today announced that the Company will be presenting a
corporate overview at three upcoming health care conferences: the UBS
Global Specialty Pharmaceuticals Conference, Deutsche Bank 31st Annual
Health Care Conference, and Rodman & Renshaw 3rd Annual Global Healthcare
Conference.
Encysive Pharmaceuticals' presentation schedule is as follows:

* UBS Global Specialty Pharmaceuticals Conference - April 24th at 3 p.m.
EDT at the Grand Hyatt Hotel in New York City
* Deutsche Bank 31st Annual Health Care Conference - May 2nd at
4 p.m. EDT at the Sheraton Hotel in Boston
* Rodman & Renshaw 3rd Annual Global Healthcare Conference - May 15th at
1 p.m. CEST (7 a.m. EDT) at Le Meridien Beach Plaza Hotel in Monte
Carlo, Monaco
A live webcast of each presentation may be viewed on the Company's web
site at http://www.encysive.com . A replay will be available for 30 days
following each respective presentation.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in
the discovery, development and commercialization of novel, synthetic, small
molecule compounds to address unmet medical needs. Our research and
development programs are predominantly focused on the treatment and
prevention of interrelated diseases of the vascular endothelium and exploit
our expertise in the area of the intravascular inflammatory process,
referred to as the inflammatory cascade, and vascular diseases. To learn
more about Encysive Pharmaceuticals please visit our web site:
http://www.encysive.com .
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements are subject to certain risks, trends and
uncertainties that could cause actual results to differ materially from
those projected. Among those risks, trends and uncertainties are our
estimate of the sufficiency of our existing capital resources, our ability
to raise additional capital to fund cash requirements for future
operations, timelines for initiating new clinical trials, planned
announcements of clinical data, the possibility of obtaining regulatory
approval, our ability to manufacture and sell any products, potential drug
candidates, their potential therapeutic effect, market acceptance or our
ability to earn a profit from sales or licenses of any drug candidate, our
ability to discover new drugs in the future, and our ability to establish
future collaborative arrangements, as well as more specific risks, trends
and uncertainties facing Encysive such as those set forth in its reports on
Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange
Commission. Given these risks, trends and uncertainties, any or all of
these forward looking statements may prove to be incorrect. Therefore you
should not rely on any such forward looking statements. Furthermore,
Encysive undertakes no duty to update or revise these forward-looking
statements. The Private Securities Litigation Reform Act of 1995 permits
this discussion.



SOURCE Encysive Pharmaceuticals Inc.
Web Site: http://www.encysive.com

[nkelchen]

Antwort auf Beitrag Nr.: 21.267.963 von nkelchen am 21.04.06 10:37:40

http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/2…

BREAKING NEWS
Show Me All Trading News Revenue Revision BREAKING NEWS Coverage Reiterated Coverage Initiated ECONOMIC NEWS SMALL STOCK FOREX NEWS Downgrade Analyst Changes Market Analysis EUROPEAN MARKETS Dividend Earnings Estimate Change STOCK ALERT ASIAN MARKETS IMPORTANT WS EVENT TOP STORY
SciClone Says Pre-Clinical Data Of SCV-07 - BCG TB Vaccine Administration Shows Enhanced Protective Effect - Quick Facts

Friday, April 21, 2006; Posted: 06:44 AM

Find out where SCLN is going
Use our most popular trading tool to find
out how SCLN will move in the next
5 days.


(RTTNews) - SciClone Pharmaceuticals Inc. (SCLN | charts | news | PowerRating) presented data from a pre-clinical study demonstrating that the administration of SCV-07 in conjunction with the BCG tuberculosis, TB, vaccine resulted in a significantly superior protective effect against Mycobacterium tuberculosis, the bacteria that cause TB, compared with the administration of the BCG vaccine alone. The data was presented at the second international conference on TB Vaccines for the World in Vienna, Austria.

Scientists at Mycos Research evaluated three escalating doses of SCV-07 used in four different administration schedules, and it was found that the highest protection against M. tuberculosis was observed in animals that received SCV-07 both before and after vaccination, at an intermediate dose.

Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved

[nkelchen]

Antwort auf Beitrag Nr.: 21.271.289 von nkelchen am 21.04.06 14:20:23

Da bin ich doch glatt in einen Kaufrausch verfallen -
wenn das meine Frau wüsste...




Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:


Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Verlust OLGC 70$ (Reduzierung 20.04.2006)
Cash:1247$-1014€ (Depotgewinne, die realisiert wurden)

Im Depot:
400 SCLN
250 NABI
250 PCYC
225 RIGL
600 OGLC
400 AGEN
600 INHX
200 RHEO
Kapitaleinsatz:6937€
Wert:8511€
Entwicklung:22,70%

aktueller Gesamtwert:9525€
Entwicklung:37,30%

Watchlist: ENCY

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Neuaufnahme mit Insiderkauf ca. 2500$
-Neuaufnahme ohne Insiderkauf ca. 1250$


Gruss
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.281.016 von nkelchen am 22.04.06 09:27:27

kleiner Überblick gefällig:
http://quotes.nasdaq.com/quote.dll?mode=stock&page=multi&sym…

nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.283.301 von nkelchen am 22.04.06 16:19:45

http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/2…

Show Me All Trading News Revenue Revision BREAKING NEWS Coverage Reiterated Coverage Initiated ECONOMIC NEWS SMALL STOCK FOREX NEWS Downgrade Analyst Changes Market Analysis EUROPEAN MARKETS Dividend Earnings Estimate Change STOCK ALERT ASIAN MARKETS IMPORTANT WS EVENT TOP STORY
SciClone Names Friedhelm Blobel President, CEO, Director - Quick Facts

Monday, April 24, 2006; Posted: 06:45 AM


(RTTNews) - SciClone Pharmaceuticals, Inc. (SCLN | charts | news | PowerRating) revealed the appointment of Friedhelm Blobel as President, Chief Executive Officer and a Director of the Company effective as of June 2, 2006.

The company said that Ira Lawrence would continue as President and Chief Executive Officer until June 2, 2006, and after that date, would serve as a consultant to the company. Lawrence also would continue to serve as a Director of the company and would serve as a member of the Business Development Committee and the newly formed Science Review Committee of the Board of Directors. Lawrence\'s resignation was for personal reasons.

Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved

[nkelchen]

Antwort auf Beitrag Nr.: 21.295.333 von nkelchen am 24.04.06 14:35:51

der nächste bitte:

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7BD54…

DOV Pharmaceutical, Inc. Announces Results for the First Phase III Trial of Bicifadine in Chronic Pain

E-mail | Print | | Disable live quotes Last Update: 4:36 PM ET Apr 24, 2006


HACKENSACK, N.J., April 24, 2006 /PRNewswire-FirstCall via COMTEX/ -- DOV Pharmaceutical, Inc. (DOVP : dov pharmaceutical inc com
News , chart, profile, more
Last: 14.69-0.09-0.61%

8:07am 04/25/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
DOVP14.69, -0.09, -0.6%) announced today high-level results recently developed from the first Phase III placebo-controlled clinical trial -- study 020 -- of its novel analgesic bicifadine in patients with chronic low back pain (CLBP). Bicifadine did not achieve a statistically significant effect relative to placebo on the primary endpoint of the study at any of the doses tested: 200 mg, 300 mg or 400 mg b.i.d. The primary endpoint as defined in the study protocol was the improvement in Visual Analog Scale (VAS) pain scores between baseline and the end of the treatment period. Initial analysis points to an unusually high placebo response rate and the extent of patients' reliability in taking their medication as potential factors in the study outcome. The trial was a U.S., multi-center, double-blind, placebo-controlled study of approximately 600 patients with CLBP who were treated for up to 12 weeks.
DOV is currently conducting a more detailed assessment of the trial data in order to better understand the factors which are responsible for these findings.
"We are disappointed by the unexpected results of our Phase III trial, study 020," said Dr. Leslie Hudson, President and Chief Executive Officer of DOV. "We are continuing forward with our Phase II trials of bicifadine in osteoarthritis and neuropathic pain and our two Phase III trials of bicifadine in CLBP, studies 021 and 022. We will provide more detailed guidance regarding our bicifadine chronic pain program once we are in a position to do so."
Conference Call
The Company will host a conference call (1-877-407-8031) beginning at 5:30 p.m. EDT on Monday, April 24, 2006. This conference call also will be Web cast and available for replay. For more information, please visit the Investor Relations page at www.dovpharm.com.
About DOV
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, pain and depression. Our partner Neurocrine has filed two NDAs for the use of DOV's compound indiplon for the treatment of insomnia.
Cautionary Note
Statements in this press release that are not historical facts constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act, each as amended, including statements regarding our expectations with respect to the progress of and level of expenses for our clinical trial programs. You can also identify forward-looking statements by the following words: may, will, should, expect, intend, plan, anticipate, believe, estimate, predict, potential, continue or the negative of these terms or other comparable terminology. We caution you that forward-looking statements are inherently uncertain and are simply point-in-time estimates based on a combination of facts and factors currently known by us about which we cannot be certain. Actual results or events will surely differ and may differ materially from our forward-looking statements as a result of many factors, some of which we may not be able to predict or may not be within our control. Such factors may also materially adversely affect our ability to achieve our objectives and to successfully develop and commercialize our product candidates, including our ability to:
* Demonstrate the safety and efficacy of product candidates at each stage
of development;
* Meet our development schedule for our product candidates, including with
respect to clinical trial initiation, enrollment and completion;
* Develop an acceptable development plan under and otherwise achieve the
results contemplated by the recent amendment to the existing license
agreement with Merck;
* Meet applicable regulatory standards and receive required regulatory
approvals on our anticipated time schedule or at all;
* Meet obligations and required milestones under our license and other
agreements;
* Obtain and maintain collaborations as required with pharmaceutical
partners;
* Obtain substantial additional funds;
* Obtain and maintain all necessary patents or licenses; and
* Produce drug candidates in commercial quantities at reasonable costs and
compete successfully against other products and companies.


Factors that may cause our actual results to differ materially from our forward-looking statements include (i) one or more of our product candidates could be shown to cause harmful side effects, (ii) one or more of our product candidates may not exhibit the expected therapeutic results, (iii) we or the FDA may place on clinical hold one or more of our clinical trials, and neither we nor the agency may determine to lift such hold, (iv) patient recruitment may be slower than expected or patients may drop out of our clinical trials, (v) regulatory approval for our product candidates may not be received or may be delayed, (vi) our licensees and collaborative partners on whom our success depends may not fulfill their obligations to us and (vii) financings that require SEC approval may be delayed. You should also refer to the risks discussed in our other filings with the Securities and Exchange Commission including those contained in our annual report on Form 10-K filed on March 15, 2006. We qualify all our forward-looking statements by these cautionary statements. There may be other factors that may materially affect our forward-looking statements and our future results. Readers should not, therefore, place undue reliance on our forward-looking statements. We do not undertake any obligation and do not intend to update any forward-looking statement.
SOURCE DOV Pharmaceutical, Inc.
Keri P. Mattox, Director, Investor Relations and Corporate Communications of DOV Pharmaceutical, Inc., [phone] http://www.prnewswire.com Copyright (C) 2006 PR Newswire. All rights reserved. ********************************************************************** As of Thursday, 04-20-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-09-2006 for DOVP @ $17.62. (C) 2006 Comtex News Network, Inc. All rights reserved.

[nkelchen]

Antwort auf Beitrag Nr.: 21.311.391 von nkelchen am 25.04.06 14:24:11

heute im Angebot:

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B3B7…

Among other early movers, Discovery Laboratories (DSCO : discovery laboratories inc new com
News , chart, profile, more
Last: 4.69-0.04-0.85%

9:05am 04/25/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
DSCO4.69, -0.04, -0.8%) tumbled 38% to $2.90 after saying late Monday that it expects a potentially significant delay in approval for its Surfaxin drug due to disappointing test results.

[nkelchen]

Antwort auf Beitrag Nr.: 21.311.391 von nkelchen am 25.04.06 14:24:11

DSCO
2Wochen nach dem ersten drawdown - schon der 2.




auch wenn mein Depot bis heute gut lief -
Es bleibt eine heikle Sache!
nk

[nkelchen]

ATLANTA, April 25 /PRNewswire-FirstCall/ -- Inhibitex, Inc. (NASDAQ:INHX) announced today that it will present at the Deutsche Bank 31st Annual Health Care Conference on Tuesday, May 2, 2006 at 4:45 p.m. EDT from the Sheraton Boston Hotel in Boston. William D. Johnston, Ph.D., president and chief executive officer of Inhibitex, Inc. will provide an update on the company and its clinical development programs.

A live audio webcast of the presentation will be available on the "Investors" section of the company\'s website at http://www.inhibitex.com/. The webcast will be archived and available on the Inhibitex website after the event for a period of 30 days.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. All of the company\'s drug development programs are based on its proprietary MSCRAMM(R) protein platform.

MSCRAMM proteins are located on the surface of pathogenic organisms and are responsible for the initiation and spread of infections. The company\'s most advanced product candidates are Veronate(R) and Aurexis(R), for which the company has retained all worldwide rights. The company\'s preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional information about the company, please visit http://www.inhibitex.com/." target="_blank" rel="nofollow ugc noopener">http://www.inhibitex.com/.

Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.

CONTACTS: Inhibitex, Inc.

Russell H. Plumb Chief Financial Officer [phone]

Laura Perry (Investors) Stern Investor Relations, Inc.

[phone]

DATASOURCE: Inhibitex, Inc.


CONTACT: Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc.,

[phone], or ; or Investors, Laura Perry of Stern

Investor Relations, Inc., [phone], or


Web site: http://www.inhibitex.com/

[nkelchen]

Antwort auf Beitrag Nr.: 21.316.334 von nkelchen am 25.04.06 18:07:26

MORGEN
nicht vergessen:
----------------

Press Release Source: Rigel Pharmaceuticals, Inc.


Rigel Announces Presentations at Two Investor Conferences
Wednesday April 19, 7:30 am ET


SOUTH SAN FRANCISCO, Calif., April 19 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that James M. Gower, Chairman and Chief Executive Officer will provide a company overview at two upcoming investor conferences:

6th Annual Fortis Bank Biotechnology Conference
Four Seasons Hotel, Park Lane, London
Wednesday, April 26
3:30 p.m. GMT
Deutsche Bank 2006 Health Care Conference
Sheraton Boston Hotel in Boston, MA
Wednesday, May 3
1:45 p.m. EDT
*Will be webcast

To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com/rigel/events. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

[nkelchen]

Antwort auf Beitrag Nr.: 21.316.528 von nkelchen am 25.04.06 18:18:09

Antigenics to Report First Quarter 2006 Financial Results on May 3, 2006; Conference Call to Follow
4/25/2006 7:00:00 AM EST
BIOWIRE

Antigenics Inc. (NASDAQ:AGEN) will release its first quarter financial results before the market opens on May 3, 2006. Antigenics executives will host a conference call at 11:00 a.m. ET that same day. To access the live call, dial 888-271-9082 (domestic) or 706-679-7741 (international); the access code is 8085047. The call will also be webcast and will be accessible from the company's website at www.antigenics.com/webcast/. A replay will be available approximately two hours after the call through midnight ET on May 17, 2006. The replay number is 800-642-1687 (domestic) or 706-645-9291 (international), and the access code is 8085047. The replay will also be available on the company's website approximately two hours after the live call.

Antigenics is a biotechnology company developing treatments for cancers, infectious diseases and autoimmune disorders. For more information, please visit www.antigenics.com.

CONTACT:
Antigenics Inc. Investor Relations: Shalini Sharp, 800-962-2436 [e-mail] or Corporate Communications: Sunny Uberoi, 212-994-8206 [e-mail]

[nkelchen]

Antwort auf Beitrag Nr.: 21.323.048 von nkelchen am 26.04.06 08:50:49

mal abwarten, ob die 200er trägt...



oder wenigstens der Bereich um 770 hält.
nk

[nkelchen]

http://yahoo.reuters.com/stocks/QuoteCompanyNewsArticle.aspx…


advertisement

Nabi Biopharmaceuticals signs deal with Sanofi
Wed Apr 26, 2006 8:46 AM ET
FACT BOX

NABI.O (Nabi Biopharmaceuticals)
Last: $6.39
Change: -0.03
Up/Down: -0.47%


MayAugNovFeb
Quote
Full Chart
Company Profile
Analyst Research
News for NABI.O
Nabi Biopharmaceuticals signs deal with Sanofi
Fresenius, Nabi sign transplantation product deal
NEW YORK, April 26 (Reuters) - Nabi Biopharmaceuticals (NABI.O: Quote, Profile, Research) on Wednesday said it has signed an agreement with a unit of Sanofi-Aventis Group (SNY.N: Quote, Profile, Research) relating to protection against exposure to rabies.

© Reuters 2006. All Rights Reserved.

[nkelchen]

Press Release Source: Nabi Biopharmaceuticals


Nabi Biopharmaceuticals Secures 'Supply and Contract Manufacturing' Agreement with Sanofi Pasteur for Anti-Rabies Product
Wednesday April 26, 8:30 am ET
- Agreement Emphasizes Nabi's Expertise in Manufacturing, Leverages Core Assets and Provides Revenue Stream -


BOCA RATON, Fla., April 26 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI - News) today announced that it has signed an agreement with Sanofi Pasteur, part of the Sanofi-Aventis Group (NYSE: SNY - News), to fractionate human plasma used for the production of Imogam® Rabies-HT (Rabies Immune Globulin [Human] USP Heat Treated). Imogam Rabies-HT provides passive protection when given immediately to individuals exposed to the rabies virus. The agreement affirms and leverages Nabi Biopharmaceuticals' core competency as a leading provider of source and specialty antibody plasma products and reflects the company's proven experience in the fractionation of immune globulins in its state-of-the-art biologicals manufacturing facility.
ADVERTISEMENT


Under the terms of the agreement, Nabi Biopharmaceuticals will fractionate human plasma containing antibodies to the rabies virus at its Boca Raton, Florida, manufacturing facility and ship the partially manufactured product to Sanofi Pasteur for completion of production at its manufacturing facility in Lyon, France. The majority of human plasma used for the production of Imogam Rabies-HT is collected by Nabi Biopharmaceuticals at its antibody collection centers in the United States.

The manufacturing agreement will allow Sanofi Pasteur to streamline the production process for Imogam Rabies-HT and allows Nabi Biopharmaceuticals to use capacity in its Boca Raton manufacturing facility, providing a seamless process from plasma collection to processing, resulting in improved production and shipping efficiency. Financial terms were not disclosed. Nabi Biopharmaceuticals expects to begin manufacturing under this agreement in the second half of 2006.

Imogam Rabies-HT is used in combination with a rabies vaccine to prevent infection caused by exposure to the rabies virus in people who have never been vaccinated against rabies. Although rabies among humans is rare in the United States, an estimated 40,000 individuals receive a post-exposure prevention treatment each year.

Raafat Fahim, Ph.D., sr. vice president, research, technical and production operations, Nabi Biopharmaceuticals, stated, "This agreement not only validates our expertise as a top provider of high-quality antibody plasma products and our deep experience in manufacturing, but it also advances our important goal to increase the cash return from our specialized operating assets. This new relationship expands our contract manufacturing business and further improves the efficiency of our strategic plasma-based products business. We are delighted to be collaborating with such an esteemed biologicals company as Sanofi Pasteur and are pleased that they have entrusted the manufacturing of this product to our company."

About Rabies

Rabies is an acute viral disease that attacks the body's central nervous system. Rabies is carried in the saliva of animals and is most commonly transmitted through bites by an infected animal. Unless treated, rabies is almost always fatal.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis and transplant, kidney disease (nephrology) and nicotine addiction. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php" target="_blank" rel="nofollow ugc noopener">http://www.nabi.com/pipeline/index.php . The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com .

Statements in this press release about the company that are not strictly historical are forward-looking statements and include statements about our products in development, the market for such products, clinical trials and studies, intellectual property position, and alliances and partnerships. You can identify these forward-looking statements because they involve our expectations, beliefs, plans, projections, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward- looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to the company's ability to advance the development of products currently in the pipeline or in clinical trials; maintain the human and financial resources to commercialize current products and bring to market products in development; obtain regulatory approval for its products in the U.S., Europe or other markets; successfully develop, manufacture and market its products; realize future sales growth for its biopharmaceutical products; secure patent positions and prevail in patent litigation; raise additional capital on acceptable terms; and re-pay its outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005 filed with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Nabi Biopharmaceuticals

[nkelchen]

Nichts ist so gut, dass man es nicht ab und an ändern sollte.
Werde meine Einkäufe doch auf dem alten Niveau belassen.

Soll meinen, Insiderkauf=1.500$
kein Insiderkauf= 750$

Gestern kamen schon wieder 2Anwärter auf die WL.
Ich habe nun 8Werte im Depot und 3auf der WL.

Da ich mir um die drawdown Gefahr in diesem Sektor bewusst bin,
halte ich die einzelnen Positionen lieber etwas kleiner.
DSCO hat Gestern gezeigt, was alles passieren kann
Die Umschichtungen haben Kosten von 88€ verursacht.


Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:


Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Verlust Umstrukturierung 158$ (Reduzierung 20.04.2006+26.04.2006)
Cash:1159$-938€ (Depotgewinne, die realisiert wurden)

Im Depot:
400 SCLN
250 NABI
250 PCYC
225 RIGL
380 OGLC
320 AGEN
380 INHX
240 RHEO

Watchlist: ENCY/DSCO/DOVP

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Neuaufnahme mit Insiderkauf ca. 1500$
-Neuaufnahme ohne Insiderkauf ca. 750$


Gruss
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.334.316 von nkelchen am 26.04.06 18:53:26

Press Release Source: OrthoLogic


OrthoLogic to Host Conference Call Discussing First Quarter 2006 Results
Thursday April 27, 9:00 am ET


TEMPE, Ariz., April 27 /PRNewswire-FirstCall/ -- OrthoLogic Corp. (Nasdaq: OLGC - News) announced today that it will release financial and operating results for 1Q2006 on Thursday, May 4, 2006.ADVERTISEMENT


Management will host a conference call and Webcast the same day at 9:00AM EDT (6:00AM MT). The call may be accessed at 866-825-1692 (domestic) or 617- 213-8059 (international), with access code 66209515, or by logging onto the Investors section of the Company's Web site, http://www.orthologic.com .

A replay will be available beginning May 4, 2006, at 11:00 AM EDT until May, 18, 2006, and may be accessed at 888-286-8010 (domestic) or 617-801-6888 (international), with access code 19681555.

About OrthoLogic

OrthoLogic is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under- served conditions. The Company is focused on the development and commercialization of two product platforms: Chrysalin® (TP508) and AZX100.

Chrysalin, the Company's novel synthetic 23-amino acid peptide, is being studied in two lead indications, both of which represent areas of significant unmet medical need -- fracture repair and diabetic foot ulcer healing. Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become a leading company focused on tissue and bone repair. The Company owns exclusive worldwide rights to Chrysalin.

AZX100 is a novel synthetic 24-amino acid peptide, the first of a new class of compounds in the field of smooth muscle relaxation called Intracellular Actin Relaxing Molecules, or ICARMs(TM). AZX100 is currently being evaluated for medically and commercially significant applications, such as the treatment of vasospasm associated with subarachnoid hemorrhage, the prevention of keloid scarring and the treatment of asthma. OrthoLogic has an exclusive worldwide license to AZX100.




--------------------------------------------------------------------------------
Source: OrthoLogic

[nkelchen]

Antwort auf Beitrag Nr.: 21.346.904 von nkelchen am 27.04.06 15:28:34

update:
---------

Der € drückt, der Index fällt, die Performance bröckelt....




Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:

Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Verlust Umstrukturierung 158$ (Reduzierung 20.04.2006+26.04.2006)
Cash:1159$ - 938€ (Depotgewinne, die realisiert wurden)


Im Depot:
400 SCLN
250 NABI
250 PCYC
225 RIGL
380 OGLC
320 AGEN
380 INHX
240 RHEO


Kapitaleinsatz:6079€
Wert:7310€
Entwicklung:20%

aktueller Gesamtwert:8248€
Entwicklung:35,70%

Watchlist: ENCY/DSCO/DOVP

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Neuaufnahme mit Insiderkauf ca. 1500$
-Neuaufnahme ohne Insiderkauf ca. 750$

[nkelchen]

Antwort auf Beitrag Nr.: 21.374.709 von nkelchen am 29.04.06 12:01:47

http://home.businesswire.com/portal/site/google/index.jsp?nd…

May 02, 2006 06:00 AM US Eastern Timezone
Zacks Sell List Highlights: Centex, SigmaTel, Nabi Biopharmaceuticals and Sirf Tech Holdings
CHICAGO--(BUSINESS WIRE)--May 2, 2006--Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List - Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Centex Corporation (NYSE:CTX) and SigmaTel, Inc. (Nasdaq:SGTL). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Nabi Biopharmaceuticals (Nasdaq:NABI) and Sirf Tech Holdings (Nasdaq:SIRF). To see the full Zacks #5 Rank List - Stocks to Sell Now visit: http://at.zacks.com/?id=92


Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List -- Stocks to Sell Now by 129.7% annually (11.9% vs. 5.2% respectively). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why CTX and SGTL have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the Zacks ranked stocks:

Centex Corporation (NYSE:CTX) reported disappointing results last week. The company said it earned $2.92 per share during its fiscal fourth-quarter, 18 cents below expectations. Looking forward, the company anticipates earning between $8.50 and $10.00 per share in fiscal 2007. Following the release of the new guidance, three of the five covering analysts cut their forecasts. The new fiscal 2007 consensus estimate, which calls for profits of $9.14 per share, $1.52 below the forecast of a week ago.

SigmaTel, Inc. (Nasdaq:SGTL) topped first-quarter expectations, but analysts significantly cut their forecasts for the remainder of the year. SGTL said losses totaled 67 cents per share in the first quarter, two cents narrower than the consensus estimate. Looking forward, the company expects GAAP losses to range between 59 cents and 66 cents per share. Analysts had been cutting their full-year forecasts prior to last week's report and lowered them even more after the report. The new consensus estimate for a full year loss of $1.42 per share is $1.66 below the consensus estimate of two months ago.

Here is a synopsis of why NABI and SIRF have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks:

Nabi Biopharmaceuticals (Nasdaq:NABI) missed earnings expectations for the third-time in four quarters. Last week, the company said that it generated a first-quarter loss of 30 cents per share, 14 cents wider than the consensus estimate. Following the report, two of the four covering analysts cut their projections for full year results. The new consensus estimate, which calls for a loss of 68 cents per share, is 19 cents below the forecast of a week ago. Sirf Tech Holdings (Nasdaq:SIRF) topped expectations last week, but that didn't stop analysts from slashing estimates. SGTL generated first-quarter profits of 17 cents per share, two cents above expectations. Following the release of the report, four of the five covering analysts cut their full-year outlook. The new consensus estimate, which calls for profits of 38 cents per share, is 45 cents below the forecast of a month ago.

Truly taking advantage of the Zacks Rank requires the understanding of how it works. The free special report; "Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions" is available to provide this insightful background. Download a free copy now to prosper in the years to come at http://at.zacks.com/?id=93

About the Zacks Rank

For over 17 years, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." Since inception in 1988, #1 Rank stocks have generated an average annual return of +33%. During the 2000-2002 bear market, Zacks #1 Rank stocks gained 43.8%, while the S&P 500 tumbled 37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have underperformed the S&P 500 by 129.7% annually (+5.2% vs. +11.9%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.

Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of Zacks #1 Rank stocks and highlights those stocks poised to outperform the market. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=94

The Zacks Rank, and all of its recommendations, is created by Zacks & Co., member NASD. Zacks.com displays the Zacks Rank with permission from Zacks & Co. on its web site for individual investors.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=95

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

(a) The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contacts
Zacks.com
Charles Rotblut, 312-630-9880 x 352
[e-mail]

[nkelchen]

Antwort auf Beitrag Nr.: 21.400.859 von nkelchen am 02.05.06 12:37:08

http://finance.yahoo.com/q/sa?s=pcyc

[nkelchen]

immerhin fast 500k gekauft..
nk

[nkelchen]

http://yahoo.reuters.com/stocks/QuoteCompanyNewsArticle.aspx…

TABLE-Rigel Q1 loss narrows
Tue May 2, 2006 7:59 AM ET
May 2 (Reuters) -
RIGEL PHARMACEUTICALS INC. (RIGL.O: Quote, Profile, Research)
Latest Forecast* No. of Yr ago
analysts qtr
Loss (diluted, $/shr) 0.34 -- -- 0.57
Net loss ($ million) 8.5 -- -- 11.2
Revenue ($ million) 9.9 6.9 2 2.6
*Source: Reuters Estimates
--The drug company said it had 24.8 million weighted
average shares in the latest quarter compared to 19.7 million
in the same period last year.
--The company said latest first-quarter results included
stock based compensation expense of $3.6 million.
--For the latest quarter, two analysts on average had
expected a loss of 36 cents a share, excluding exceptional
items, according to Reuters Estimates.
(Reporting by Jennifer Robin Raj in Bangalore)

[nkelchen]

Antwort auf Beitrag Nr.: 21.403.305 von nkelchen am 02.05.06 15:45:33

http://www.streetinsider.com/news.php?id=812433&st=b

Basic Content
Inhibitex (INHX) Terminates Agreement With Nabi BioPharma (NABI); INHX to Pay $3.3 Million
04-28-2006 12:55:09 PM
Inhibitex, (Nasdaq: INHX) provided written notification to Nabi BioPharmaceuticals (Nasdaq: NABI)) that it was terminating the Production Agreement originally dated December 5, 2001 and as amended to date.

The purpose of the Agreement was for Nabi to contract manufacture the donor-selected immune globulin form of Veronate that Inhibitex used as clinical trial material for its Veronate program. Inhibitex terminated the Agreement pursuant to Section 15.2 (b), which provides, among other things, that Inhibitex can terminate the Agreement, with immediate effect, if it decides to cancel substantially all further activity towards approval of the form of Veronate manufactured by Nabi.

On April 28, 2006 the company announced that it did not foresee performing additional clinical trials in very low birth weight infants with its current donor-selected immune globulin form of Veronate manufactured by Nabi, based on the results of the Phase III trial for Veronate.

On April 26, 2006 Nabi invoiced Inhibitex for approximately $3.3 million for such cancellation penalties associated with forecasted future production that Nabi contends are due as a result of the termination. Inhibitex does not believe that termination will result in any material penalties.

Stocks Mentioned
INHX: $2.00
Change ($): 0.01
Change (%): 0.50
Volume: 81509

NABI: $6.10
Change ($): -0.14
Change (%): -2.24
Volume: 529883

[nkelchen]

http://finance.yahoo.com/q/sa?s=nabi

[nkelchen]

http://yahoo.reuters.com/stocks/QuoteCompanyNewsArticle.aspx…

TABLE-Antigenics Q1 loss narrows
Wed May 3, 2006 7:38 AM ET
May 3 (Reuters) -
ANTIGENICS INC. (AGEN.O: Quote, Profile, Research)
Latest Yr ago
qtr
Loss^(diluted, $/shr) 0.36 0.40
Net loss ($ million) 16.1 18.0
Net loss attributable to
common stockholders
($ million) 16.3 18.2
Revenue ($ thousands) 60 120
^ Attributable to common stockholders
--The biotechnology company said it incurred a non-cash
charge of $0.9 million or 2 cents a share in the latest first
quarter related to expensing of stock-based compensation.
--For the latest first quarter, two analysts on average had
expected the company to post a loss of 35 cents a share,
excluding exceptional items, on revenue of $0.2 million,
according to Reuters Estimates.
(Reporting by Debojyoti Ghosh

[nkelchen]

Press Release Source: Rigel Pharmaceuticals, Inc.


Rigel to Present at Upcoming Scientific Conferences
Wednesday May 3, 7:30 am ET


SOUTH SAN FRANCISCO, Calif., May 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that it will be presenting at two upcoming scientific conferences. Details are as follows:
May 4, 2006: Spring Pulmonary Research Group Symposium 2006 -- Upper Airway Disease: Clinical and Research Perspectives at Johns Hopkins University, Baltimore, Maryland


Presentation Time: Thursday, May 4th, 10:00-10:50 a.m. EDT
Title: "Targeting Syk Kinase for Allergic Airway Disease"
Presenter: Esteban Masuda, Ph.D., Senior Director of Immunology, Rigel

May 10-12, 2006: 2nd Annual PharmaDiscovery conference in North Bethesda, Maryland


Presentation Time: Friday, May 12th, 8:00-9:30 a.m. EDT
Track 3: Innovative Approaches to Therapeutic Areas
Title: "Development of Aurora Kinase Inhibitor R763 for the Treatment of
Cancer"
Presenter: Yasumichi Hitoshi, M.D., Ph.D, Senior Director of Oncology,
Rigel


About Rigel (www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue pre-clinical and clinical development of product candidates and the timing thereof and the potential efficacy and safety of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects," "believes," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005. Rigel does not undertake any obligation to update forward-looking statements.


CONTACT:
Raul Rodriguez
[phone]
[e-mail]

MEDIA CONTACT:
Carolyn Bumgardner Wang
WeissComm Partners, Inc.
[phone]
[e-mail]




--------------------------------------------------------------------------------
Source: Rigel Pharmaceuticals, Inc.

[nkelchen]

SciClone Reports First Quarter 2006 Results
SAN MATEO, CA -- (MARKET WIRE) -- 05/03/2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the first quarter ended March 31, 2006. For the first quarter 2006, revenues from the sale of ZADAXIN®, SciClone's lead product, increased by 17% to $7,789,000, compared with ZADAXIN revenues of $6,661,000 reported for the first quarter 2005. This increase in product revenues for the first quarter 2006 is primarily attributable to an increase in the quantity of ZADAXIN sold to the Chinese market, which accounts for over 90% of overall ZADAXIN sales. Contract revenue for the first quarter 2006 was $90,000 compared with $134,000 for the first quarter 2005.

Net loss for the first quarter 2006 was $2,424,000, or $0.05 per share, an increase of 62% from the net loss of $1,494,000, or $0.03 per share, reported for the first quarter 2005. This increase is primarily due to $674,000 incurred in the 2006 period relating to the expensing of stock options as now required under the new accounting regulation "Share-Based Payment" (SFAS 123R). Gross margin for the first quarter 2006 was consistent with the levels of recent quarters. Gross margin was significantly higher for the first quarter 2005 mostly due to lower average cost of product sold in that period.

"During the first quarter, we saw continued ZADAXIN sales growth in China, resolved our dispute with Schering Plough KK, and received Orphan Drug designation from the Food and Drug Administration for ZADAXIN in the treatment of stage IIb through stage IV malignant melanoma," commented Ira D. Lawrence, M.D., President and Chief Executive Officer of SciClone Pharmaceuticals, Inc. "Looking ahead, preparations are well underway to begin a phase 1 oral comparison trial with our second drug candidate, SCV-07, in May, and we are planning to begin an influenza vaccine sparing trial with SCV-07 in the fourth quarter. In addition, we look forward to reporting further data from the large phase 2 malignant melanoma trial, using ZADAXIN, in the second half of this year."

Dr. Lawrence added, "Although my role will change moving forward, I am committed to SciClone's advancement and I look forward to assisting Dr. Blobel and the company particularly concerning product development and the expansion of our product offerings for the Chinese market."

Research and development expenses for the first quarter 2006 totaled $3,829,000, a 10% increase from $3,481,000 for the equivalent period of 2005. This increase is primarily attributable to expenses relating to the development of SciClone's second drug candidate, SCV-07, which offset a decrease in expenses relating to the clinical development of ZADAXIN and charges in the 2006 period relating to the expensing of certain stock options as now required under SFAS 123R.

Sales and marketing expenses for the first quarter 2006 were $2,832,000, a 22% increase from $2,328,000 for the first quarter of 2005. The increase is primarily due to increased conference-related and brochure and publication expenses, and to the expensing of certain stock options as now required under SFAS 123R.

General and administrative expenses for the first quarter 2006 were $2,387,000, a 47% increase from $1,620,000 for the first quarter 2005. This increase is attributable to increased personnel and consulting costs, and the expensing of certain stock options as now required under SFAS 123R.

Cash, cash equivalents and short-term investments totaled $37,530,000 at March 31, 2006, compared with $42,256,000 at December 31, 2005 and $47,053,000 at March 31, 2005. The cash balance at March 31, 2006 does not include $8,000,000 that was received from Schering Plough KK (SPKK) in April 2006 and will be recognized as income in the second quarter 2006.

Financial Guidance for Full Year 2006

SciClone is adjusting its financial guidance for the full year 2006 primarily to reflect the effects of the $8,000,000 received from the settlement and expensing of stock options as now required under SFAS 123R. SciClone maintains its guidance for revenues from the sale of ZADAXIN for the full year 2006 of approximately $32,000,000. Research and development expenses for the full year 2006 are projected to be approximately $14,600,000. Primarily due to the income effect of the settlement and lower projected related legal expense, SciClone is adjusting its guidance from a net loss for the full year 2006 to an expectation of approximately break-even. Similarly, SciClone is revising its estimate for ending cash, cash equivalents and short-term investments at December 31, 2006 from $29,000,000 to $38,000,000.

In January 2006, the Company adopted Financial Accounting Standards Board Statement No.123 (revised 2004), "Share-Based Payment" (SFAS 123R) requiring share-based payments to employees and directors, including grants of stock options, to be recognized in the statement of operations based on their fair values.

Recent Developments

-- In April, SciClone announced the appointment of Friedhelm Blobel,
Ph.D. as President, Chief Executive Officer and a Director of the Company,
effective as of June 2, 2006. Ira Lawrence, M.D. will continue as President
and CEO until June 2, 2006, and after that date, will serve as a consultant
to the Company. Dr. Lawrence also will continue to serve as a Director of
the Company and will serve as a member of the Business Development
Committee and the newly formed Science Review Committee of the Board of
Directors. Dr. Lawrence resigned for personal reasons.

-- In April, ZADAXIN received regulatory approval in Brazil for sale as
an immunomodulator indicated for use as an adjuvant to the influenza
vaccine in immune suppressed patients and elderly persons, and as an
adjuvant to the hepatitis B vaccine in patients with chronic hemodialysis
who have not obtained sufficient antibody titers from prior vaccination.

-- In April, SciClone announced the presentation of pre-clinical data
demonstrating that the administration of SCV-07 in conjunction with the BCG
tuberculosis (TB) vaccine in mice resulted in a significantly superior
protective effect against Mycobacterium tuberculosis, the bacteria that
cause TB, compared with the administration of the BCG vaccine alone.
Importantly, these data suggest that SCV-07 primes the cellular immune
response, so that, following TB vaccination the immune system is able to
mount a stronger defense against the infection than it could with the
vaccine alone. Dr. Todd M. Lasco, Director of Microbiology at Mycos
Research, LLC, presented these data at the second international conference
on TB Vaccines for the World in Vienna, Austria.

-- In April, SciClone announced that it had reached a settlement in its
dispute with SPKK concerning clinical trials conducted in Japan with
ZADAXIN, SciClone's lead compound. Under this resolution, SciClone received
$8,000,000 from SPKK. Although SciClone's immediate focus for ZADAXIN
remains the pursuit of regulatory approvals in the United States and
Europe, SciClone plans to re-evaluate its development strategy in Japan
with ZADAXIN.

-- In March, the Food and Drug Administration (FDA) granted orphan drug
designation to thymalfasin, the active ingredient of ZADAXIN, for the
treatment of stage IIb through stage IV malignant melanoma. Should ZADAXIN
receive regulatory approval for malignant melanoma from the FDA, Orphan
Drug designation could provide SciClone with seven years of market
exclusivity in the United States.

Conference Call
SciClone will host a conference call at 11:30 a.m. ET (8:30 a.m. PT) today, Wednesday, May 3, 2006. The call will contain forward-looking statements. Financial and statistical information to be discussed in the conference call will be posted on the investor relations section of SciClone's web site at www.sciclone.com prior to the commencement of the conference call.

DATE: Wednesday, May 3, 2006

TIME: 11:30 a.m. ET (8:30 a.m. PT)

WEBCAST: Live call and replay accessible at www.sciclone.com

LIVE CALL: 800-817-4887 (U.S./Canada)
913-981-4913 (international)

About SciClone
SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products to market in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.

The information in this press release contains forward-looking statements including our expectations and beliefs regarding future sales and financial results for 2006, and progress and results of our clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, goals, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including changes in demand for ZADAXIN, the progress or failure of clinical trials, our actual experience in executing on our objectives, the performance of our partners, maintenance of the sufficiency and eligibility of the enrolled patient population, unanticipated delays or additional expenses incurred during our clinical trials, our future cash requirements, delays in analyzing and synthesizing data obtained from clinical trials, future actions of our strategic partners, unexpected delays in preparation for enrollment, future actions by the U.S. Food and Drug Administration or equivalent regulatory authorities in Europe and the fact that experimental data and clinical results derived from studies with a limited group of patients may not be predictive of the results of larger studies, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.


SCICLONE PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

Three months ended
March 31,
2006 2005
------------ ------------

Product sales $ 7,789,000 $ 6,661,000
Contract revenue 90,000 134,000
------------ ------------

Total revenues 7,879,000 6,795,000
Cost of product sales 1,566,000 997,000
------------ ------------

Gross margin 6,313,000 5,798,000

Operating expenses:
Research and development 3,829,000 3,481,000
Sales and marketing 2,832,000 2,328,000
General and administrative 2,387,000 1,620,000
------------ ------------
Total operating expenses 9,048,000 7,429,000
------------ ------------

Loss from operations (2,735,000) (1,631,000)

Interest and investment income 352,000 233,000
Interest and investment expense (41,000) (90,000)
Other income (expense), net - (6,000)
------------ ------------

Net loss $ (2,424,000) $ (1,494,000)
============ ============

Basic and diluted net loss per share $ (0.05) $ (0.03)
============ ============

Weighted average shares used in computing basic
and diluted net loss per share 45,891,878 44,699,777
============ ============


SCICLONE PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS

ASSETS

March 31, December 31,
2006 2005
------------ ------------
(unaudited)
Current assets:
Cash and cash equivalents $ 23,073,000 $ 25,845,000
Restricted short-term investments 693,000 692,000
Other short-term investments 13,764,000 15,719,000
Accounts receivable, net of allowance of
$97,000 in 2006 and $82,000 in 2005 11,320,000 9,701,000
Inventories 3,809,000 3,272,000
Prepaid expenses and other current assets 1,747,000 1,890,000
------------ ------------
Total current assets 54,406,000 57,119,000
Property and equipment, net 350,000 380,000
Intangible assets, net 455,000 472,000
Other assets 1,525,000 1,544,000
------------ ------------
Total assets $ 56,736,000 $ 59,515,000
============ ============

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable $ 1,564,000 $ 626,000
Accrued compensation and employee benefits 830,000 1,960,000
Accrued professional fees 663,000 642,000
Other accrued expenses 2,280,000 1,687,000
Accrued clinical trials expense 1,861,000 1,658,000
Deferred revenue 151,000 211,000
Convertible notes payable - 1,600,000
------------ ------------
Total current liabilities 7,349,000 8,384,000
Other long-term liabilities - 68,000
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.001 par value; 10,000,000
shares authorized; no shares outstanding in
2006 and 2005 - -
Common stock; $0.001 par value; 75,000,000
shares authorized; 45,899,107 and 45,877,420
shares issued and outstanding in 2006 and
2005, respectively 46,000 46,000
Additional paid-in capital 210,990,000 210,245,000
Accumulated other comprehensive income 56,000 53,000
Accumulated deficit (161,705,000) (159,281,000)
------------ ------------
Total stockholders' equity 49,387,000 51,063,000
------------ ------------
Total liabilities and stockholders' equity $ 56,736,000 $ 59,515,000
============ ============


SCICLONE PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

Three months ended
March 31,
2006 2005
------------ ------------

Operating activities:
Net loss $ (2,424,000) $ (1,494,000)
Adjustments to reconcile net loss to net cash
used in operating activities:
Stock-based compensation 674,000 -
Depreciation and amortization 64,000 55,000
Changes in operating assets and liabilities:
Accounts receivable (1,619,000) (1,497,000)
Inventories (508,000) 785,000
Prepaid expenses and other assets 156,000 424,000
Accounts payable and other accrued expenses 1,531,000 (783,000)
Accrued compensation and employee benefits (1,130,000) (935,000)
Accrued clinical trials expenses 203,000 (387,000)
Accrued professional fees 21,000 185,000
Long-term liabilities (68,000) (544,000)
Deferred revenue (60,000) (134,000)
------------ ------------
Net cash used in operating activities (3,160,000) (4,325,000)
------------ ------------

Investing activities:
Purchases of property and equipment (11,000) (20,000)
Sales (purchases) of short-term investments 1,957,000 (52,000)
------------ ------------
Net cash provided by (used in) investing
activities 1,946,000 (72,000)
------------ ------------

Financing activities:
Proceeds from issuances of common stock, net
of financing costs 42,000 104,000
Repayment of notes payable (1,600,000) -
------------ ------------
Net cash (used in) provided by financing
activities (1,558,000) 104,000
------------ ------------

Net decrease in cash and cash equivalents (2,772,000) (4,293,000)
Cash and cash equivalents, beginning of period 25,845,000 41,204,000
------------ ------------
Cash and cash equivalents, end of period $ 23,073,000 $ 36,911,000
============ ============







--------------------------------------------------------------------------------


Corporate contact:
Becky Horner
Investor Relations
SciClone Pharmaceuticals, Inc.
650-358-3437


SOURCE: SciClone Pharmaceuticals, Inc.

--------------------------------------------------------------------------------

Back To Recent News
Issuers of news releases, not Market Wire, are solely responsible for the accuracy of the content.

[nkelchen]

Antwort auf Beitrag Nr.: 21.416.476 von nkelchen am 03.05.06 14:30:02

Habe halbe Posi RIGL mit ca. 25% Gewinn verkauft.
Der Chart macht mir Sorgen...
nk

[Bioperle]

Hi lieber nkelchen,

schau Dir mal www.mologen.com an.

Ein gefallener Engel mit unglaublichen Kurspotential.

[nkelchen]

Antwort auf Beitrag Nr.: 21.418.783 von Bioperle am 03.05.06 16:53:36

Danke für den Hinweis.
Passt leider nicht zu meinen Kriterien...

RIGL habe ich nun ganz verscherbelt - der Chart ist eine Zumutung




nk

[nkelchen]

Press Release Source: OrthoLogic Corp.


OrthoLogic Announces First Quarter 2006 Financial Results
Thursday May 4, 8:00 am ET


TEMPE, Ariz., May 4 /PRNewswire-FirstCall/ -- OrthoLogic Corp. (Nasdaq: OLGC - News) today announced financial results for the first quarter of 2006.
ADVERTISEMENT


OrthoLogic reported a net loss of $16.5 million, or $0.42 per share, for the first quarter of 2006, compared to a net loss of $5.5 million and $0.14 per share for the first quarter of 2005. Comparability between periods was affected by the inclusion in 2006 of $8.4 million of purchased in-process research and development costs related to the AzERx acquisition, $1 million in non-cash stock compensation costs associated with the adoption of SFAS123® effective January 1, 2006 and increased research and development costs resulting from a greater number of active subjects in the Chrysalin Phase 3 and Phase 2b fracture repair human clinical trials.

At March 31, 2006, OrthoLogic had cash, cash equivalents, and investments of $80.8 million.

"We remain committed to our goal of building a successful biopharmaceutical organization and developing therapeutic solutions that satisfy significant unmet medical needs," stated Jock Holliman, Executive Chairman of OrthoLogic. "Topline Phase 3 clinical trial results showed that Chrysalin at the 10ug dose did not meet the primary endpoint of time to removal of immobilization. However, in this study -- as in the study that preceded it -- Chrysalin was demonstrated to be safe and to improve bone healing, based on radiographic evidence. We are currently conducting an interim analysis of our Phase 2b dose-ranging clinical trial assessing Chrysalin in distal radius fracture. For the balance of 2006, we will direct our efforts toward optimizing the value of Chrysalin in the fracture repair indication, examining its potential in diabetic foot ulcer healing, and advancing our AZX100 product platform."

Quarterly Highlights

Chrysalin Programs: The Company reported topline Phase 3 clinical trial results of Chrysalin in distal radius fracture in March, showing that 10ug of Chrysalin did not meet the primary endpoint of time to removal of immobilization. Chrysalin was shown to be safe and to improve bone healing based on radiographic evidence. The Company is conducting an interim analysis of the concurrent Phase 2b dose-ranging clinical trial assessing Chrysalin in distal radius fracture at 1ug, 3ug, 10ug and 30ug, with results expected during the third quarter of 2006.

Business Development: OrthoLogic expanded its pipeline in February with the acquisition from AzERx of an exclusive license for the core intellectual property relating to the lead compound AZX100, a 24-amino acid peptide. OrthoLogic also announced in February the formation of a strategic alliance with Quintiles, one of the world's leading pharmaceutical services organizations, for the development of Chrysalin.

Management Update: During the first quarter of 2006, OrthoLogic appointed Les Taeger as Senior Vice President and Chief Financial Officer of OrthoLogic. The Company also appointed William M. Wardell, MD, Ph.D., to its Board of Directors. In April 2006, the Company announced the resignation of James M. Pusey, MD as President and CEO, and the appointment of John M. Holliman, III as Executive Chairman and Randolph C. Steer, MD, Ph.D. as President.

Conference Call Information

Management will host a conference call and webcast on May 4, 2006 at 9:00 AM EDT (7:00 AM MT). To access the call, participants may dial 866-825-1692 (domestic) or 617-213-8059 (international) and provide the access code 66209515.

A replay of the call will be available beginning May 4, 2006, at 11:00 AM EDT until May 18, 2006, and may be accessed at 888-286-8010 (domestic) or 617-801-6888 (international), with access code 19681555.

Additionally, the conference call will be webcast on the Investor Relations section of the Company's Web site, www.orthologic.com.

About OrthoLogic

OrthoLogic is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served conditions. The Company is focused on the development and commercialization of two product platforms: Chrysalin® (TP508) and AZX100.

Chrysalin, the Company's novel synthetic 23-amino acid peptide, is being studied in two lead indications, both of which represent areas of significant unmet medical need -- fracture repair and diabetic foot ulcer healing. Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become a leading company focused on tissue repair. The Company owns exclusive worldwide rights to Chrysalin.

AZX100 is a novel synthetic pre-clinical 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation called Intracellular Actin Relaxing Molecules, or ICARMs(TM). AZX100 is currently being evaluated for medically and commercially significant applications, such as the treatment of vasospasm associated with subarachnoid hemorrhage, the prevention of keloid scarring and the treatment of asthma. OrthoLogic has an exclusive worldwide license to AZX100.

OrthoLogic's corporate headquarters are in Tempe, Arizona. For more information, please visit the Company's Web site: www.orthologic.com.

Statements in this press release or otherwise attributable to OrthoLogic regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which include the timing and acceptability of FDA filings and the efficacy and marketability of potential products, involve risks and uncertainties that could cause actual results to differ materially from predicted results. These risks include: delays in obtaining or inability to obtain FDA, institutional review board or other regulatory approvals of preclinical or clinical testing; unfavorable outcomes in our preclinical and clinical testing; the development by others of competing technologies and therapeutics that may have greater efficacy or lower cost; delays in obtaining or inability to obtain FDA or other necessary regulatory approval of our products; our inability to successfully and cost effectively develop or outsource manufacturing and marketing of any products we are able to bring to market; changes in FDA or other regulations that affect our ability to obtain regulatory approval of our products, increase our manufacturing costs or limit our ability to market our products; our possible need for additional capital in the future to fund the continued development of our product candidates; and other factors discussed in our Form 10-K for the fiscal year ended December 31, 2005, and other documents we file with the Securities and Exchange Commission.




ORTHOLOGIC CORP.
(A Development Stage Company)
CONDENSED BALANCE SHEETS
(in thousands)
(Unaudited)

March 31, December 31,
2006 2005
ASSETS

Current assets
Cash and cash equivalents $41,429 $35,111
Short-term investments 32,389 46,437
Prepaids and other current assets 756 857

Total current assets 74,574 82,405

Furniture and equipment, net 593 525
Long-term investments 6,974 2,084
Deferred income taxes 1,106 1,106
Patents, net 2,240 2,223

Total assets $85,487 $88,343

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
Accounts payable $1,516 $1,036
Accrued compensation 262 711
Accrued clinical 737 544
Accrued severance and other
restructuring costs 410 602
Other accrued liabilities 800 1,089
Total current liabilities 3,725 3,982

Deferred rent and other non-current
liabilities 454 183
Total liabilities $4,179 $4,165

Stockholders' Equity
Common Stock $.0005 par value; 20 19
100,000,000 and 50,000,000 shares
authorized; 40,573,489
38,124,742 shares issued and outstanding
Additional paid-in capital 184,965 171,355
Accumulated deficit (103,677) (87,196)
Total stockholders' equity 81,308 84,178
Total liabilities and
stockholders' equity $85,487 $88,343



ORTHOLOGIC CORP.
(A Development Stage Company)
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)

Development
Stage Company
August 5,
Three months ended 2004 -
March 31, March 31,
2006 2005 2006
OPERATING EXPENSES
General and administrative $2,093 $910 $8,881
Research and development 6,716 5,403 40,240
Other divestiture and
related gains -- (250) (375)
Purchased in-process
research and development 8,434 -- 34,274
Total operating
expenses 17,243 6,063 83,020
Interest income, net (762) (552) (4,153)
Loss from continuing
operations before taxes 16,481 5,511 78,867
Income tax benefit -- (12) (750)
Loss from continuing
operations 16,481 5,499 78,117
Discontinued operations - net
gain on sale of the bone
device business, net
of taxes ($267) -- -- (2,202)
NET LOSS $16,481 $5,499 $75,915

Per Share Information:
Net loss, basic and
diluted $(0.42) $(0.14)
Basic and diluted shares
outstanding 39,250,851 38,047,198





--------------------------------------------------------------------------------
Source: OrthoLogic Corp.

[nkelchen]

Antwort auf Beitrag Nr.: 21.401.093 von nkelchen am 02.05.06 12:54:26

KORREKTUR!!

es waren nur Optionen - keine Insiderkäufe!

http://www.secform4.com/insider/showhistory.php?cik=inhx

also doch vorerst nur die halbe Portion ins Depot...
nk

[Mannitrader]

Antwort auf Beitrag Nr.: 21.436.400 von nkelchen am 04.05.06 21:10:18

Hallo nkelchen!

Ich beobachte die Akite von Inhibitex schon lange und kann mich einfach nicht entscheiden, ob ich kaufen möchte...

Laut deine Aussage vom 02.05.06 hast du doch nachgelegt oder??
und von Bioperformer hat von Insiderkäufern gesprochen..(im Inhibitex-Thread)

Jetzt bin ich aber unsicher!!

Nabe läuft und läuft..Mist, habe leider zu früh verkauft..Aber nicht schlimm..

Gruß Mannitrader

[nkelchen]

Antwort auf Beitrag Nr.: 21.436.764 von Mannitrader am 04.05.06 21:32:36

Hallo Manni,
habe die Posi wieder halbiert!
Gruss
nk

[nkelchen]

125Nabi zu 7,05 verkauft.
225RIGL zu 10,10 verkauft.


Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:

Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Gewinn NABI 438$ (100%Gewinn-04.05.2006): 1,275=343,50€
Gewinn RIGL 497$ (Position wegen Charttechnik aufgelöst 04.05.2006): 1,275=390€
Verlust Umstrukturierung 158$ (Reduzierung 20.04.2006+26.04.2006)
Cash:2094$ - 1671€ (Depotgewinne, die realisiert wurden)


Im Depot:
400 SCLN
125 NABI
250 PCYC
380 OGLC
320 AGEN
375 INHX
240 RHEO


Kapitaleinsatz:4288€
Wert:4652€
Entwicklung:8,5% (Währungsentwicklung eingerechnet)

aktueller Gesamtwert:6323€
Entwicklung:47,4%

Watchlist: ENCY/DSCO/DOVP

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Neuaufnahme mit Insiderkauf ca. 1500$
-Neuaufnahme ohne Insiderkauf ca. 750$


Wegen der starken Währungsschwankungen, hier die damaligen Kaufkurse, auf die sich auch die Gewinnregelung bezieht.

20.04.06 Ankauf 380 Stück (INHIBITEX INC.) zu 2,03 €
19.04.06 Ankauf 240 Stück (OCCULOGIX INC.) zu 3,16 €
13.04.06 Ankauf 320 Stück (ANTIGENICS INC. DE) zu 2,32 €
04.04.06 Ankauf 380 Stück (ORTHOLOGIC CORP. D) zu 2,10 €
20.12.05 Ankauf 400 Stück (SCICLONE PHARM. IN) zu 2,06 €
15.12.05 Ankauf 250 Stück(PHARMACYCLICS D)zu 3,55€
27.11.05 Ankauf 250 Stück (NABI BIOPHA.) zu 3,54 €

[nort.]

[nkelchen]

Antwort auf Beitrag Nr.: 21.485.487 von nort. am 09.05.06 10:17:54

Ob der Phantasie Index die Kurve wieder kriegt?



nk

[nort.]

zwar kein Bio, aber

Insiderkäufe
und Absturz

ATOSS SOFTWARE AG

[nort.]

Antwort auf Beitrag Nr.: 21.513.144 von nort. am 10.05.06 21:22:44

[nort.]

Antwort auf Beitrag Nr.: 21.513.144 von nort. am 10.05.06 21:22:44

[nkelchen]

Antwort auf Beitrag Nr.: 21.513.144 von nort. am 10.05.06 21:22:44

Holla, hatte ich noch überhaupt nicht gesehen.
Schaue ich mir auf jeden Fall an.
Danke
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.514.072 von nkelchen am 10.05.06 22:11:14

na ja -
5,50€ Sonderausschüttung!
nk

[nort.]

Antwort auf Beitrag Nr.: 21.514.131 von nkelchen am 10.05.06 22:15:10

kommt nächstes Mal wieder

[nkelchen]

Antwort auf Beitrag Nr.: 21.527.738 von nort. am 11.05.06 19:33:14

habe gerade ne mini Posi zu 3,19 erstanden:

Threshold says FDA puts its TH-070 program on hold
Thu May 11, 2006 5:31 PM ET
Printer Friendly | Email Article | Reprints | RSS

LOS ANGELES, May 11 (Reuters) - Threshold Pharmaceuticals Inc (THLD.O: Quote, Profile, Research) said on Thursday that the U.S. Food and Drug Administration had placed the company's TH-070 clinical development program for benign prostatic hyperplasia on partial clinical hold because of liver enzyme level abnormalities.

The company said that it was amending phase 3 of its European and Canadian trial to discontinue dosing.



© Reuters 2006. All Rights Reserved.

[nkelchen]

Frustkäufe gefällig...?!
Habe gerade einige Positionen vergrössert.

Die werden allerdings nur als Tradingposition geführt.
Entweder habe ich heute günstig nachgekauft, oder...

nk

[nkelchen]

update -
downgrade

Der Dollar schmiert ab, der Index auch....



Es werden nur Nasdaq-Biotech Werte berücksichtigt!
Es sollte ein Gap von mindestens 50% entstanden sein.

Stand Rebound-Depot-De05:

Gewinn PCYC 435$ (50%Gewinn-12.01.2006)
Gewinn SCLN 420$ (50%Gewinn-16.03.2006)
Gewinn NABI 462$ (50%Gewinn-22.03.2006)
Gewinn NABI 438$ (100%Gewinn-04.05.2006): 1,275=343,50€
Gewinn RIGL 497$ (Position wegen Charttechnik aufgelöst 04.05.2006): 1,275=390€
Verlust Umstrukturierung 158$ (Reduzierung 20.04.2006+26.04.2006)
Cash:2094$ - 1671€ (Depotgewinne, die realisiert wurden)


Im Depot:
400 SCLN
125 NABI
250 PCYC
380 OGLC
320 AGEN
375 INHX
240 RHEO


Kapitaleinsatz:4288€
Wert:4250€
Entwicklung:-1% (Währungsentwicklung eingerechnet)

aktueller Gesamtwert:5921€
Entwicklung:+38%

Watchlist: ENCY/DSCO/THLD

zum Thema Exit:
-halbe Position wird nach 50%Gewinn aufgelöst.
-die verbliebene Position wird bei erzielten 100%
zur Hälfte aufgelöst.
-restliche Position unterliegt keiner festen Exit-Regel.
-SL(nach 50%Gewinn)ist Einstandspreis.
-SL(nach 100%Gewinn)ist 50%Gewinn.
-Neuaufnahme mit Insiderkauf ca. 1500$
-Neuaufnahme ohne Insiderkauf ca. 750$


Wegen der starken Währungsschwankungen, hier die damaligen Kaufkurse, auf die sich auch die Gewinnregelung bezieht.

[nkelchen]

Antwort auf Beitrag Nr.: 21.545.681 von nkelchen am 13.05.06 09:28:34

"May is one of the most dangerous months to speculate in stocks. The other dangerous months are
July, January, September, April, November, October, March, June, December, August and February"
Mark Twain


Wie Recht Er doch hat...
nk

[nort.]

Antwort auf Beitrag Nr.: 21.548.025 von nkelchen am 13.05.06 11:52:51

muss ich mir merken, der ist wirklich gut

[nkelchen]

sold PCYC 250 zu 3,97
und tschüss!
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.591.737 von nkelchen am 15.05.06 17:59:25

und
sold SCLN 400 zu 2,60
nk

[nkelchen]

UPDATE 1-Pfizer, Neurocrine gets mixed nod for sleep drug
Tue May 16, 2006 8:23 AM ET
(Recasts, adds details, share reaction)

WASHINGTON, May 16 (Reuters) - Neurocrine Biosciences Inc. (NBIX.O: Quote, Profile, Research) said on Tuesday a high dosage of a new sleep drug it is developing with Pfizer Inc.(PFE.N: Quote, Profile, Research) was rejected by U.S. regulators, sending shares lower in premarket trading.

FACT BOX

NBIX.O (Neurocrine Biosciences Inc)
Last: $54.63
Change: +1.89
Up/Down: +3.58%


JunSepDecMar
Quote
Full Chart
Company Profile
Analyst Research
News for NBIX.O
UPDATE 1-Pfizer, Neurocrine gets mixed nod for sleep drug
Pfizer, Neurocrine gets mixed nod for sleep drug
UPDATE 1-TABLE-Neurocrine Biosciences Q1 loss widens
Neurocrine said the U.S. Food and Drug Administration said the drug called indiplon could be approved in its 5 milligram and 10 milligram doses but not the 15 milligram XR version of the tablets.

Neurocrine, whose shares fell 30 percent in premarket trading, said it is disappointed with the FDA's decision and will meet with the agency to discuss the next steps.

Some analysts had predicted indiplon's peak annual sales could top $1 billion.

The drug would compete with several other treatments for insomnia such as Sepracor Inc's (SEPR.O: Quote, Profile, Research) Lunesta, Sanofi-Aventis SA's (SASY.PA: Quote, Profile, Research) (SNY.N: Quote, Profile, Research) Ambien and Takeda Pharmaceutical Co.'s (4502.T: Quote, Profile, Research) Rozerem.

Neurocrine said the FDA indicated that they did not have an opportunity to review all of the information submitted during the new drug application review cycles.

Shares of Neurocrine fell 30 percent on the Inet electronic brokerage to $38.50, while Pfizer's shares slipped 0.2 percent in premarket trading.

[nkelchen]

Antwort auf Beitrag Nr.: 21.605.143 von nkelchen am 16.05.06 14:38:58

DOVP will es schon wieder wissen...!!
nk

[nort.]

böööööööööööööööööööööööse



un nu schaquen wir doch mal was diese Woche noch so kommt...

[nort.]

[nkelchen]

der ist auch nich schlecht:



AP
Dov Pharmaceutical Pain Drug Fails Trial
Monday May 22, 6:01 pm ET
Dov Pharmaceutical Back Pain Drug Bicifadine Fails Phase 3 Clinical Trial, Has Limited Results


HACKENSACK, N.J. (AP) -- Dov Pharmaceutical Inc. provided more details Monday on a failed clinical trial of its lead drug candidate bicifadine, saying the treatment failed to show significant results in half the participants.
ADVERTISEMENT


Last month the company said the drug, aimed at treating chronic lower back pain, proved ineffective and that it would conduct a more detailed analysis of the phase 3 clinical trial results. It blamed the failure on a high placebo response rate.

The analysis did show that as the severity of chronic low back pain worsened, the drug had a more significant effect. For example, patients with low back pain that radiated down the leg -- or sciatica -- were twice as responsive to treatment and patients with moderate to severe disability due to back pain had only one-third the placebo response of patients with mild to moderate disabilities. In all, the drug was effective on half the patients in the study.

"While we are surprised and disappointed by the trial failure, we are encouraged by the effect of bicifadine in the two major subgroups," said Dr. Warrent Stern, senior vice president of drug development, in a statement.

The company said it will continue its phase 3 trial, amending part of it by enrolling only patients who meet the subgroup criteria of severe pain or sciatica.

Another part of the trial is already fully enrolled and will be used to provide the safety database necessary to file for approval.

Also, the drug is in a phase 2 clinical trial, also to test its effectiveness, with the focus on osteoarthritis patients.

Dov also said it will delay seven Phase 1 clinical trials necessary to file a new drug application with the Food and Drug Administration, saying they are short in duration and can be completed close to the filing date.

Dov also will delay a manufacturing scale-up that would have been required if it was going to file a new drug application for bicifadine in the first half of 2007.

The company added that it will cut $9 million out of the program budget as a result of restructuring the various clinical trials associated with bicifadine.

Dov Pharmaceutical develops drugs to treat central nervous system and cardiovascular disorders. Shares of the company's stock fell 2.7 percent, or 8 cents, to close at $2.92 on the Nasdaq. They recently traded up 2 cents in aftermarket activity, according to Inet.

[nort.]

Antwort auf Beitrag Nr.: 21.763.649 von nkelchen am 23.05.06 19:09:50

tja so einfach ist es. Kaum schiebt man den Bären aus Bayern ab, kommt der Dax raus...

[nort.]

APHT.PK ist pleite!



fragt man sich nur was mit der Pipe passieren wird...

[puhvogel]

Antwort auf Beitrag Nr.: 21.785.021 von nort. am 24.05.06 19:07:46

Das ist erstaunlich schnell mit denen bergab gegangen, obwohl sie keineswegs nur schlechte Nachrichten produziert haben. . Die haben mal 45 Dollar gekostet.

[nort.]

[nort.]

[GerdKill]

[GerdKill]

[GerdKill]

[GerdKill]

holla, da war aber wer zuversichtlich...